{"id":9162,"date":"2024-12-23T12:11:27","date_gmt":"2024-12-23T12:11:27","guid":{"rendered":"https:\/\/jbbssrrealtors.com\/xenobiotics\/?page_id=9162"},"modified":"2025-06-12T07:48:49","modified_gmt":"2025-06-12T07:48:49","slug":"denmark","status":"publish","type":"page","link":"https:\/\/xenobiotics.in\/index.php\/denmark\/","title":{"rendered":"Denmark"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Generic Medicine Drugs<\/h1><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
S. NO.<\/strong><\/th>NAME OF PRODUCT<\/strong><\/th>COMPOSITION<\/strong><\/th>OFFICIAL
\nPHARMACOPOEIA<\/strong><\/th>		DCGI DATE<\/strong><\/th>PP DATE <\/strong><\/th>\n<\/tr>\n<\/thead>\n
1<\/td>ACECLOFENAC TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, April 05, 2007<\/td><\/td>\n<\/tr>\n
2<\/td>CIPROFLOXACIN HYDROCHLORIDE TABLETS IP 500 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nCIPROFLOXACIN HYDROCHLORIDE IP
\nEQ TO CIPROFLOXACIN 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, May 01, 1989<\/td><\/td>\n<\/tr>\n
3<\/td>DICYCLOMINE HYDROCHLORIDE & PARACETAMOL TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nDICYCLOMINE HYDROCHLORIDE IP 20 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.<\/td>		 <\/td><\/td><\/td>\n<\/tr>\n
4<\/td>ETODOLAC 400 MG & PARACETAMOL 325 MG TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nETODOLAC IP 400 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
5<\/td>PARACETAMOL TABLETS IP 500 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
6<\/td>DROTAVERINE HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nDROTAVERINE HYDROCHLORIDE IP 80 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
7<\/td>DICLOFENAC SODIUM & PARACETAMOL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 50 MG
\nPARACETAMOL IP 500 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Wednesday, January 30, 2008<\/td><\/td>\n<\/tr>\n
8<\/td>DICLOFENAC GEL IP<\/td>COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ TO DICLOFENAC SODIUM 1.00% W\/W
\nBENZYL ALCOHOL IP 1.00%W\/W
\n(AS PRESERVATIVE)
\nGEL BASE Q.S.<\/td>		IP<\/td>Friday, March 01, 1991<\/td><\/td>\n<\/tr>\n
9<\/td>ISOTRETINOIN CAPSULES IP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nISOTRETINOIN IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS<\/td>		IP<\/td>Friday, June 21, 2002<\/td><\/td>\n<\/tr>\n
10<\/td>URSODEOXYCHOLIC ACID TABLETS IP 300 MG<\/td>EACH FILM COATED TABLET CONATINS
\nURSODEOXYCHOLIC ACID IP 300 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, April 12, 2001<\/td><\/td>\n<\/tr>\n
11<\/td>DICLOFENAC DIETHYLAMINE, MENTHOL & METHYL
\nSALICYLATE GEL<\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ TO DICLOFENAC SODIUM 1.00% W\/W
\nMENTHOL IP 5.00% W\/W
\nMETHYL SALICYLATE IP 10.00% W\/W
\nGEL BASE Q.S.<\/td>		<\/td>Sunday, August 17, 2014<\/td><\/td>\n<\/tr>\n
12<\/td>ESCITALOPRAM OXALATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nESCITALOPRAM OXALATE IP
\nEQ. TO ESCITALOPRAM 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, December 12, 2007<\/td><\/td>\n<\/tr>\n
13<\/td>ITRACONAZOLE GEL 1% W\/W<\/td>COMPOSITION
\nITRACONAZOLE BP 1.00% W\/W
\nMETHYL PARABEN IP 0.10% W\/W
\nPROPYL PARABEN IP 0.05% W\/W
\nIN A GEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
14<\/td>LOSARTAN POTASSIUM TABLETS IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nLOSARTAN POTTASIUM IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, June 16, 1998<\/td><\/td>\n<\/tr>\n
15<\/td>ESCITALOPRAM OXALATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nESCITALOPRAM OXALATE IP
\nEQ. TO ESCITALOPRAM 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, January 24, 2003<\/td><\/td>\n<\/tr>\n
16<\/td>LEVETIRACETAM TABLETS BP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVETIRACETAM IP 750 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, April 05, 2005<\/td><\/td>\n<\/tr>\n
17<\/td>ESOMEPRAZOLE GASTRO- RESISTANT TABLETS IP 40 MG<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ TO ESOMEPRAZOLE 40 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, December 04, 2001<\/td><\/td>\n<\/tr>\n
18<\/td>IVERMECTIN & ALBENDAZOLE TABLETS<\/td>EACH UNCOATED CHEWABLE TABLET CONTAINS IVERMECTIN IP 12 MG
\nALBENDAZOLE IP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Saturday, April 25, 2009<\/td><\/td>\n<\/tr>\n
19<\/td>IVERMECTIN & ALBENDAZOLE TABLETS<\/td>EACH UNCOATED CHEWABLE TABLET CONTAINS IVERMECTIN IP 6 MG
\nALBENDAZOLE IP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Saturday, April 25, 2009<\/td><\/td>\n<\/tr>\n
20<\/td>OMEPRAZOLE MAGNESIUM & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nOMEPRAZOLE MAGNESIUM IP
\nEQ TO OMEPRAZOLE 10 MG
\nDOMPERIDONE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
21<\/td>ALBENDAZOLE AND IVERMECTIN SUSPENSION <\/td>EACH 5 ML CONTAINS
\nALBENDAZOLE IP 200 MG
\nIVERMECTIN IP 1.5 MG
\nFLAVOURED SYRUP BASE
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
22<\/td>ACICLOVIR DISPERSIBLE TABLETS IP 800 MG<\/td>EACH DISPERSIBLE UNCOATED TABLET CONTAINS
\nACICLOVIR IP 800 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
23<\/td>LEVOCETIRIZINE DIHYDROCHLORIDE & MONTELUKAST TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nMONTELUKAST SODIUM IP
\nEQ. TO MONTELUKAST 10 MG
\nLEVOCETIRIZINE DIHYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, January 31, 2008<\/td><\/td>\n<\/tr>\n
24<\/td>CIPROFLOXACIN HYDROCHLORIDE & ORNIDAZOLE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCIPROFLOXACIN HYDROCHLORIDE IP
\nEQ TO CIPROFLOXACIN 500 MG
\nORNIDAZOLE IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, February 03, 2003<\/td><\/td>\n<\/tr>\n
25<\/td>ALBENDAZOLE SUSPENSION IP<\/td>EACH 5 ML CONTAINS
\nALBENDAZOLE IP 200 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Saturday, February 01, 1986<\/td><\/td>\n<\/tr>\n
26<\/td>PROPRANOLOL HYDROCHLORIDE (SR) & FLUNARIZINE DIHYDROCHLORIDE CAPSULES<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 40 MG
\n(AS SUSTAINED RELEASE)
\nFLUNARIZINE DIHYDROCHLORIDE BP
\nEQ TO FLUNARIZINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATN CAPSULE SHELL<\/td>		<\/td>Tuesday, March 16, 2010<\/td><\/td>\n<\/tr>\n
27<\/td>ALBENDAZOLE CHEWABLE TABLETS IP 400 MG<\/td>EACH UNCOATED CHEWABLE TABLET CONTAINS
\nALBENDAZOLE IP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Saturday, February 01, 1986<\/td><\/td>\n<\/tr>\n
28<\/td>AMBROXOL HYDROCHLORIDE, GUAIPHENESIN, TERBUTALINE SULPHATE & MENTHOL SYRUP<\/td>EACH 10 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 30 MG
\nGUAIPHENESIN IP 100 MG
\nTERBUTALINE SULPHATE IP 2.5 MG
\nMENTHOL IP 5 MG
\nFLAVOURED SYRUPY BASE. Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
29<\/td>KETOROLAC TROMETHAMINE DISPERSIBLE TABLETS<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nKETOROLAC TROMETHAMINE IP 10 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>Wednesday, April 29, 2015<\/td><\/td>\n<\/tr>\n
30<\/td>NORTRIPTYLINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nNORTRIPTYLINE HYDROCHLORIDE IP
\nEQ.TO NORTRIPTYLINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
31<\/td>ACICLOVIR DISPERSIBLE TABLETS IP 400 MG<\/td>EACH DISPERSIBLE UNCOATED TABLET CONTAINS
\nACICLOVIR IP 400 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
32<\/td>CIPROFLOXACIN HYDROCHLORIDE TABLETS IP 250 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nCIPROFLOXACIN HYDROCHLORIDE IP
\nEQ TO CIPROFLOXACIN 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, May 01, 1989<\/td><\/td>\n<\/tr>\n
33<\/td>DICLOFENAC DIETHYLAMINE, OLIUM LINI,MENTHOL , METHYL
\nSALICYLATE & BENZYL ALCOHOL GEL<\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16 % W\/W
\nEQ TO DICLOFENAC SODIUM 1.0 % W\/W
\nOLEUM LINI BP 3.0 % W\/W
\n(CONT. PREDOMINANTLY a-LINOLENIC ACID)
\nMETHYL SALICYLATE IP 10.0 % W\/W
\nMENTHOL IP 5.0 % W\/W
\nBENZYL ALCOHOL IP 1.0 % W\/W
\n(AS PERSERVATIVE)
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
34<\/td>PROPRANOLOL HYDROCHLORIDE SUSTIANED RELEASE TABLETS<\/td>EACH UNCOATED SUSTAINED RELEASE TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
35<\/td>CIPROFLOXACIN AND TINIDAZOLE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCIPROFLOXACIN HYDROCHLORIDE IP
\nEQ TO CIPROFLOXACIN 500 MG
\nTINIDAZOLE IP 600 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
36<\/td>SILDENAFIL CITRATE TABLETS IP 100 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nSILDENAFIL CITRATE IP
\nEQ.TO SILDENAFIL 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, January 08, 2001<\/td><\/td>\n<\/tr>\n
37<\/td>AMBROXOL HYDROCHLORIDE &
\nCETIRIZINE HYDROCHLORIDE TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 60 MG
\nCETIRIZINE HYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
38<\/td>LEVOCETIRIZINE HYDROCHLORIDE & PHENYLEPHRINE HYDROCHLORIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nLEVOCETIRIZINE HYDROCHLORIDE IP 2.5 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
39<\/td>PROPRANOLOL HYDROCHLORIDE SUSTAINED RELEASE TABLETS<\/td>EACH SUSTAINED RELEASE UNCOATED TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 40 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
40<\/td>FLUOXETINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ TO FLUOXETINE 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
41<\/td>PROPRANOLOL HYDROCHLORIDE (SUSTAINED RELEASE) &
\n FLUNARIZINE DIHYDROCHLORIDE CAPSULES<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 40 MG
\n(AS SUSTAINED RELEASE)
\nFLUNARIZINE DIHYDROCHLORIDE BP
\nEQ TO FLUNARIZINE 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULES SHELLS <\/td>		<\/td>Saturday, March 13, 2010<\/td><\/td>\n<\/tr>\n
42<\/td>PROPRANOLOL HYDROCHLORIDE TABLETS IP 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q. S
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1971-November <\/td><\/td>\n<\/tr>\n
43<\/td>PROPRANOLOL HYDROCHLORIDE (EXTENDED RELEASE) &
\n FLUNARIZINE DIHYDROCHLORIDE TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 40 MG
\n(AS EXTENDED RELEASE)
\nFLUNARIZINE DIHYDROCHLORIDE IP
\nEQ TO FLUNARIZINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Saturday, March 13, 2010<\/td><\/td>\n<\/tr>\n
44<\/td>FLUOXETINE HYDROCHLORIDE CAPSULES IP 20 MG<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ. TO FLUOXETINE 20 MG
\nEXCIPIENT Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELLS <\/td>		IP<\/td>1990-March<\/td><\/td>\n<\/tr>\n
45<\/td>ORNIDAZOLE & POVIDONE IODINE OINTMENT <\/td>COMPOSITION
\nPOVIDONE IODINE IP 5.0 % W\/W
\n(0.5%W\/W AVAILABLE IODINE)
\nORNIDAZOLE IP 1.0 % W\/W
\nWATER SOLUBLE OINTMENT BASE Q.S.<\/td>		<\/td>Tuesday, January 03, 2012<\/td><\/td>\n<\/tr>\n
46<\/td>FLUOXETINE HYDROCHLORIDE CAPSULES IP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ. TO FLUOXETINE 1.0 MG
\nEXCIPIENT Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELLS<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
47<\/td>FLUOXETINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ TO FLUOXETINE 0.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULES SHELLS <\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
48<\/td>PROPRANOLOL HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 0.5 MG
\nEXCIPIENTS Q. S
\nAPPROVED COLOUR USED <\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
49<\/td>POVIDONE IODINE OINTMENT BP<\/td>COMPOSITION
\nPOVIDONE IODINE IP 5% W\/W
\n(0.5%W\/W AVAILABLE IODINE)
\nOINTMENT BASE Q.S.<\/td>		USP<\/td>Wednesday, November 01, 1972<\/td><\/td>\n<\/tr>\n
50<\/td>SUCRALFATE & POVIDONE IODINE OINTMENT <\/td>COMPOSITION
\nPOVIDONE IODINE IP 5.00% W\/W
\n(AVAILABLE IODINE 0.50% W\/W
\nSUCRALFATE IP 7.0% W\/W
\nWATER SOLUBLE OINTMENT BASE Q.S.<\/td>		<\/td>Tuesday, August 23, 2005<\/td><\/td>\n<\/tr>\n
51<\/td>POVIDONE IODINE OINTMENT BP<\/td>COMPOSITION
\nPOVIDONE IODINE IP 10.0 % W\/W
\n(1.0 %W\/W AVAILABLE IODINE)
\nWATER WASHABLE BASE Q.S.<\/td>		USP<\/td>Wednesday, November 01, 1972<\/td><\/td>\n<\/tr>\n
52<\/td>FLUOXETINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ. TO FLUOXETINE 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
53<\/td>AMBROXOL HYDROCHLORIDE, GUAIPHENESIN &
\nPHENYLEPHRINE HYDROCHLORIDE SYRUP<\/td>		EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG
\nGUAIPHENESIN IP 50 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 2.5 MG
\nIN A FLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
54<\/td>AMLODIPINE & ATENOLOL TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nATENOLOL IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, May 20, 1996<\/td><\/td>\n<\/tr>\n
55<\/td> AMBROXOL HYDROCHLORIDE, GUAIPHENESIN, TERBUTALINE
\nSULPHATE & MENTHOL SYRUP<\/td>		EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG
\nGUAIPHENESIN IP 50 MG
\nTERBUTALINE SULPHATE IP 2.5 MG
\nMENTHOL IP 2.5 MG
\nFLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
56<\/td>TOPIRAMATE TABLETS IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nTOPIRAMATE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, August 23, 1999<\/td><\/td>\n<\/tr>\n
57<\/td>OFLOXACIN & TINIDAZOLE TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nOFLOXACIN IP 200 MG
\nTINIDAZOLE IP 600 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
58<\/td>TRANEXAMIC ACID & ETAMSYLATE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nTRANEXAMIC ACID IP 250 MG
\nETAMSYLATE BP 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Wednesday, December 29, 2004<\/td><\/td>\n<\/tr>\n
59<\/td>CINNARIZINE & DOMPERIDONE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nCINNARIZINE IP 20 MG
\nDOMPERIDONE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Saturday, February 01, 1992<\/td><\/td>\n<\/tr>\n
60<\/td>AMLODIPINE & ATENOLOL TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nS-AMLODIPINE BESYLATE IP
\nEQ TO S-AMLODIPINE 2.5 MG
\nATENOLOL IP 50 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Thursday, October 17, 2002<\/td><\/td>\n<\/tr>\n
61<\/td>OLANZAPINE MOUTH DISSOLVING TABLETS<\/td>EACH MOUTH DISSOLVING UNCOATED TABLET CONTAINS
\nOLANZAPINE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, January 27, 2000<\/td><\/td>\n<\/tr>\n
62<\/td>ETORICOXIB TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 60 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, March 01, 2004<\/td><\/td>\n<\/tr>\n
63<\/td>LEVOFLOXACIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVOFLOXACIN HEMIHYDRATE IP
\nEQ TO LEVOFLOXACIN 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, July 23, 1999<\/td><\/td>\n<\/tr>\n
64<\/td>CINNARIZINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCINNARIZINE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, August 01, 1985<\/td><\/td>\n<\/tr>\n
65<\/td>CINNARIZINE & DOMPERIDONE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nCINNARIZINE IP 75 MG
\nDOMPERIDONE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
66<\/td>ETORICOXIB TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 120 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, March 01, 2004<\/td><\/td>\n<\/tr>\n
67<\/td>NORTRIPTYLINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nNORTRIPTYLINE HYDROCHLORIDE IP
\nEQ.TO NORTRIPTYLINE 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
68<\/td>BECLOMETHASONE DIPROPIONATE, CLOTRIMAZOLE & NEOMYCIN
\nCREAM<\/td>		COMPOSITION
\nBECLOMETHASONE DIPROPIONATE IP 0.05 % W\/W
\nCLOTRIMAZOLE IP 1.00 % W\/W
\nNEOMYCIN SULPHATE IP
\nEQ. TO NEOMYCIN BASE 0.50 % W\/W
\nCREAM BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
69<\/td>AMLODIPINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, December 08, 2005<\/td><\/td>\n<\/tr>\n
70<\/td>OLANZAPINE MOUTH DISSOLVING TABLETS<\/td>EACH UNCOATED MOUTH DISSOLVING TABLET CONTAINS
\nOLANZAPINE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Saturday, May 17, 2014<\/td><\/td>\n<\/tr>\n
71<\/td>AMLODIPINE & TELMISARTAN TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nAMLODIPINE BESYLATE IP
\nEQ TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>Wednesday, August 30, 2006<\/td><\/td>\n<\/tr>\n
72<\/td>CINNARIZINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCINNARIZINE IP 75 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, September 02, 2004<\/td><\/td>\n<\/tr>\n
73<\/td>IVERMECTIN TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS
\nIVERMECTIN IP 12 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		U.S.P<\/td><\/td><\/td>\n<\/tr>\n
74<\/td>AMLODIPINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ.TO AMLODIPINE 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, May 19, 1993<\/td><\/td>\n<\/tr>\n
75<\/td>AMISULPRIDE TABLETS IP 50 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nAMISULPRIDE IP 50 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Friday, March 12, 2010<\/td><\/td>\n<\/tr>\n
76<\/td>OLANZAPINE MOUTH DISSOLVING TABLETS<\/td>EACH UNCOATED MOUTH DISSOLVING TABLET CONTAINS
\nOLANZAPINE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, January 27, 2000<\/td><\/td>\n<\/tr>\n
77<\/td>TRIHEXYPHENIDYL HYDROCHLORIDE & TRIFLUOPERAZINE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nTRIHEXYPHENIDYL HYDROCHLORIDE IP 2 MG
\nTRIFLUOPERAZINE HYDROCHLORIDE IP
\nEQ. TO TRIFLUOPERAZINE 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
78<\/td>LINEZOLID TABLETS IP 600 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nLINEZOLID IP 600 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Sunday, May 30, 2004<\/td><\/td>\n<\/tr>\n
79<\/td>SERTACONAZOLE NITRATE CREAM 2% W\/W<\/td>COMPOSITION
\nSERTACONAZOLE NITRATE IP 2.0 % W\/W
\nPRESERVATIVE
\nBENZYL ALCOHOL IP 1.0% W\/W
\nCREAM BASE Q.S.<\/td>		<\/td>Thursday, January 31, 2008<\/td><\/td>\n<\/tr>\n
80<\/td>ETORICOXIB & THIOCOLCHICOSIDE TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 60 MG
\nTHIOCOLCHICOSIDE IP 4 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, November 17, 2008<\/td><\/td>\n<\/tr>\n
81<\/td>LINEZOLID ORAL SUSPENSION<\/td>EACH 5 ML RECONSTITUTED SUSPENSION CONTAINS
\nLINEZOLID IP 100 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, October 04, 2001<\/td><\/td>\n<\/tr>\n
82<\/td>TRIHEXYPHENIDYL HYDROCHLORIDE & RISPERIDONE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nRISPERIDONE IP 2 MG
\nTRIHEXYPHENIDYL HYDROCHLORIDE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
83<\/td>LINEZOLID TABLETS <\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nLINEZOLID IP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, October 04, 2001<\/td><\/td>\n<\/tr>\n
84<\/td>IVERMECTIN CREAM<\/td>COMPOSITION
\nIVERMECTIN IP 1.00%W\/W
\nCREAM BASE Q.S.<\/td>		<\/td>Wednesday, June 01, 1988<\/td><\/td>\n<\/tr>\n
85<\/td>IVERMECTIN TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS
\nIVERMECTIN IP 6 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>2004-June<\/td><\/td>\n<\/tr>\n
86<\/td>TELMISARTAN & HYDROCHLORTHIAZIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nTELMISARTAN IP 80 MG
\nHYDROCHLORTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, August 29, 2003<\/td><\/td>\n<\/tr>\n
87<\/td>IVERMECTIN SHAMPOO<\/td>COMPOSITION
\nIVERMECTIN IP 0.50%W\/V
\nAQUEOUS BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Wednesday, June 01, 1988<\/td><\/td>\n<\/tr>\n
88<\/td>TRIHEXYPHENIDYL HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nTRIHEXYPHENIDYL HYDROCHLORIDE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
89<\/td>TELMISARTAN & CHLORTHALIDONE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nCHLORTHALIDONE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
90<\/td>RISPERIDONE &TRIHEXYPHENIDYL HYDROCHLORIDE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nRISPERIDONE IP 3 MG
\nTRIHEXYPHENIDYL HYDROCHLORIDE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Wednesday, March 05, 2014<\/td><\/td>\n<\/tr>\n
91<\/td>TELMISARTAN TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, November 25, 2002<\/td><\/td>\n<\/tr>\n
92<\/td>TELMISARTAN & HYDROCHLORTHIAZIDE TABLETS IP <\/td>EACH FILM COATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, August 29, 2003<\/td><\/td>\n<\/tr>\n
93<\/td>FLUVOXAMINE MALEATE SUSTIANED RELEASE TABLETS <\/td>EACH UNCOATED SUSTAINED RELEASE TABLET CONTAINS
\nFLUVOXAMINE MALEATE BP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Wednesday, August 19, 2009<\/td><\/td>\n<\/tr>\n
94<\/td>AMISULPRIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nAMISULPRIDE IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, March 12, 2010<\/td><\/td>\n<\/tr>\n
95<\/td>CYPROHEPTADINE HYDROCHLORIDE SYRUP IP<\/td>EACH 5 ML CONTAINS
\nCYPROHEPTADINE HYDROCHLORIDE IP 2 MG
\n(ANHYDROUS)
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
96<\/td>SUCRALFATE, METRONIDAZOLE & LIGNOCAINE HYDROCHORIDE CREAM<\/td>COMPOSITION
\nSUCRALFATE IP 7.0%W\/W
\nMETRONIDAZOLE IP 1.00%W\/W
\nLIGNOCAINE HYDROCHLORIDE IP 4.0%W\/W
\nCREAM BASE Q.S.<\/td>		<\/td>Monday, August 23, 2004<\/td><\/td>\n<\/tr>\n
97<\/td>SUCRALFATE, METRONIDAZOLE & POVIDONE IODINE OINTMENT<\/td>COMPOSITION
\nSUCRALFATE BP 7.0%W\/W
\nMETRONIDAZOLE IP 1.00%W\/W
\nPOVIDONE IODINE IP 5.0%W\/W
\n(AVIALABLE IODINE 0.50%W\/W)
\nIN OINTMENT BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
98<\/td>ARTEMETHER & LUMEFENTRINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nARTEMETHER IP 80 MG
\nLUMEFANTRINE IP 480 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, June 24, 2008<\/td><\/td>\n<\/tr>\n
99<\/td>ARTEMETHER & LUMEFENTRINE TABLETS IP<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nARTEMETHER IP 40 MG
\nLUMEFANTRINE IP 240 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, June 24, 2008<\/td><\/td>\n<\/tr>\n
100<\/td>ISOXSUPRINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nISOXSUPRINE HYDROCHLORIDE IP 20 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
101<\/td>AMOROLFINE HYDROCHLORIDE CREAM<\/td>COMPOSITION
\nAMOROLFINE HYDROCHLORIDE IP
\nEQ. TO AMOROLFINE 0.25%W\/W
\nCREAM BASE Q.S.<\/td>		<\/td>Tuesday, November 25, 2003<\/td><\/td>\n<\/tr>\n
102<\/td>AMITRIPTYLINE HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMITRIPTYLINE HYDROCHLORIDE IP
\nEQ TO AMITRIPTYLINE 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
103<\/td>AMITRIPTYLINE HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMITRIPTYLINE HYDROCHLORIDE IP
\nEQ TO AMITRIPTYLINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
104<\/td>ISOXSUPRINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nISOXSUPRINE HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
105<\/td>FLUVOXAMINE MALEATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nFLUVOXAMINE MALEATE IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, February 21, 2000<\/td><\/td>\n<\/tr>\n
106<\/td>SILYMARIN TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nSILYMARIN 70 MG
\n(AS SILYBIN)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, June 22, 1995<\/td><\/td>\n<\/tr>\n
107<\/td>CYPROHEPTADINE HYDROCHLORIDE & TRICHOLINE CITRATE
\nDROPS <\/td>		EACH ML CONTAINS
\nCYPROHEPTADINE HCL IP 1.5 MG
\n(ANHYDROUS)
\nTRICHOLINE CITRATE (65%) IP 55 MG
\nFLAVOURED NON SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
108<\/td>HALOBETASOLE PROPIONATE & SALICYLIC ACID OINTMENT<\/td>COMPOSITION
\nHALOBETASOLE PROPIONATE USP 0.05% W\/W
\nSALICYLIC ACID IP 6.0% W\/W
\nOINTMENT BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
109<\/td>CLINDAMYCIN PHOSPHATE GEL BP<\/td>COMPOSITION
\nCLINDAMYCIN PHOSPHATE IP
\nEQ. TO CLINDAMYCIN 1% W\/W
\nPRESERVATIVE
\nSODIUM METHYL PARABEN IP 0.114% W\/W
\nSODIUM PROPYL PARABEN IP 0.056% W\/W
\nGEL BASE Q.S.<\/td>		BP<\/td>Thursday, January 19, 2012<\/td><\/td>\n<\/tr>\n
110<\/td>CLOBAZAM TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCLOBAZAM IP 10 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Tuesday, November 11, 1997<\/td><\/td>\n<\/tr>\n
111<\/td>ISOXSUPRINE SUSTAINED RELEASE TABLETS <\/td>EACH UNCOATED SUSTAINED RELEASE TABLET CONTAINS
\nISOXSUPRINE HYDROCHLORIDE IP 40 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>1979-May <\/td><\/td>\n<\/tr>\n
112<\/td>SILYMARIN TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nSILYMARIN 140 MG
\n(AS SILYBIN)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, June 22, 1995<\/td><\/td>\n<\/tr>\n
113<\/td>ISOXSUPRINE HYDROCHLORIDE CAPSULES<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nISOXSUPRINE HYDROCHLORIDE IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN HARD GELATIN CAPSULES SHELL<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
114<\/td>CHOLINE SALICYLATE, LIGNOCAINE HYDROCHLORIDE
\n& BENZALKONIUM CHLORIDE GEL GEL <\/td>		COMPOSITION
\nCHOLINE SALICYLATE SOLUTION BP
\nEQ.TO CHOLINE SALICYLATE 8.70% W\/W
\nLIGNOCAINE HYDROCHLORIDE IP 2.00% W\/W
\nBENZALKONIUM CHLORIDE SOLUTION IP 0.01% W\/W
\n(AS PRESERVATIVE)
\nIN PLEASANT FLAVOURED GEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
115<\/td>MEFENAMIC ACID &
\nDICYCLOMINE HYDROCHLORIDE TABLETS IP<\/td>		EACH UNCOATED TABLET CONTAINS
\nMEFENAMIC ACID IP 250 MG
\nDICYCLOMINE HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
116<\/td>GAMMABENZENE HEXACHLORIDE & CETRIMIDE LOTION<\/td>COMPOSITION
\nGAMMABENZENE HEXACHLORIDE IP 1.0% W\/V
\nCETRIMIDE IP 0.1% W\/V
\nIN EMULSION BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
117<\/td>SILYMARIN SUSPENSION<\/td>EACH 5 ML CONTAINS
\nSILYMARIN (AS SILYBIN) 35 MG
\nFLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
118<\/td>CYPROHEPTADINE HYDROCHLORIDE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCYPROHEPTADINE HYDROCHLORIDE IP
\nEQ, TO CYPROHEPTADINE(ANHYDROUS) 4 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>1973-January<\/td><\/td>\n<\/tr>\n
119<\/td>CHLORDIAZEPOXIDE TABLET IP<\/td>EACH FILM COATED TABLET CONTAINS
\nCHLORDIAZEPOXIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
120<\/td>WHITE SOFT PARAFFIN & LIGHT LIQUID PARAFFIN CREAM <\/td>COMPOSITION
\nWHITE SOFT PARAFFIN IP 13.2% W\/W
\nLIGHT LIQUID PARAFFIN IP 10.2% W\/W
\nCREAM BASE Q.S.<\/td>		<\/td>Saturday, April 26, 2014<\/td><\/td>\n<\/tr>\n
121<\/td>TRICHOLINE CITRATE & SORBITOL SOLUTION<\/td>EACH 5 ML CONTAINS
\nTRICHOLINE CITRATE (65%) 275 MG
\nSORBITOL SOLUTION (70%) IP 3.5 GM
\nFLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
122<\/td>HALOBETASOLE PROPIONATE & SALICYLIC ACID OINTMENT<\/td>COMPOSITION
\nHALOBETASOLE PROPIONATE BP 0.05% W\/W
\nSALICYLIC ACID IP 2.0% W\/W
\nOINTMENT BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
123<\/td>PRIMAQUINE PHOSPHATE DISPERSIBLE TABLETS IP<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nPRIMAQUINE PHOSPHATE IP
\nEQ TO PRIMAQUINE 2.5 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
124<\/td>SALICYLIC ACID OINTMENT IP<\/td>COMPOSITION
\nSALICYLIC ACID IP 12.0% W\/W
\nOINTMENT BASE Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
125<\/td>DI-SODIUM HYDROGEN CITRATE SYRUP<\/td>EACH 5 ML CONTAINS
\nDI-SODIUM HYDROGEN CITRATE BP 1.38 MG
\nFLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
126<\/td>CLINDAMYCIN & NICOTINAMIDE GEL <\/td>COMPOSITION
\nCLINDAMYCIN PHOSPHATE IP
\nEQ. TO CLINDAMYCIN 1.0% W\/W
\nNICOTINAMIDE IP 4.0% W\/W
\nIN ALOE, ALLANTION BASE WITH ETHYL LACTATE
\nGEL BASE Q.S.<\/td>		<\/td>Thursday, January 19, 2012<\/td><\/td>\n<\/tr>\n
127<\/td>PAROXETINE HYDROCHLORIDE
\nPROLONGED RELEASE TABLETS IP<\/td>		EACH FILM COATED PROLONGED RELEASE TABLET CONTAINS
\nPAROXETINE HYDROCHLORIDE IP
\nEQ TO PAROXETINE 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
128<\/td>CALAMINE & ZINC OXIDE SKIN LOTION IP<\/td>COMPOSITION
\nCALAMINE IP 15 % W\/V
\nZINC OXIDE IP 5 % W\/V
\nAQUEOUS BASE Q.S.<\/td>		IP <\/td><\/td><\/td>\n<\/tr>\n
129<\/td>SERTRALINE HYDROCHLORIDE TABLETS IP 100 Mg<\/td>EACH FILM COATED TABLET CONTAINS
\nSERTRALINE HYDROCHLORIDE IP
\nEQ TO SERTRALINE 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, February 23, 2004<\/td><\/td>\n<\/tr>\n
130<\/td>RISPERIDONE ORALLY DISINTEGRATING TABLETS IP<\/td>EACH ORALLY DISINTEGRATING TABLET CONTAINS
\nRISPERIDONE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
131<\/td>PAROXETINE HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nPAROXETINE HYDROCHLORIDE
\nHEMIHYDRATE IP
\nEQ TO PAROXETINE 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, October 04, 2000<\/td><\/td>\n<\/tr>\n
132<\/td>LEVETIRACETAM TABLETS IP 500 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVETIRACETAM IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, April 05, 2005<\/td><\/td>\n<\/tr>\n
133<\/td>RISPERIDONE MOUTH DISSOLVING TABLETS<\/td>EACH UNCOATED MOUTH DISSOLVING TABLET CONTAINS
\nRISPERIDONE IP 1.0 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
134<\/td>DESVENLAFAXINE GASTRO-RESISTANT TABLETS<\/td>EACH FILM COATED GASTRO-RESISTANT TABLET CONTAINS
\nDESVENLAFAXINE SUCCINATE
\nEQ. TO DESVENLAFAXINE 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		 <\/td>Monday, July 20, 2009<\/td><\/td>\n<\/tr>\n
135<\/td>CHLORDIAZEPOXIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nCHLORDIAZEPOXIDE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
136<\/td>DIVALPROEX SODIUM GASTRO-RESISTANT TABLETS IP 250 MG<\/td>EACH ENTERIC-COATED GASTRO-RESISTANT TABLET CONTAINS
\nDIVALPROEX SODIUM IP
\nEQ TO VALPROIC ACID 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, January 17, 2002<\/td><\/td>\n<\/tr>\n
137<\/td>PRIMAQUINE PHOSPHATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nPRIMAQUINE PHOSPHATE IP
\nEQ TO PRIMAQUINE 7.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
138<\/td>DIVALPROEX SODIUM GASTRO-RESISTANT TABLETS IP 500 MG<\/td>EACH ENTERIC-COATED GASTRO-RESISTANT TABLET CONTAINS.
\nDIVALPROEX SODIUM IP
\nEQ TO VALPROIC ACID 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, January 17, 2002<\/td><\/td>\n<\/tr>\n
139<\/td>PRIMAQUINE PHOSPHATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nPRIMAQUINE PHOSPHATE IP
\nEQ TO PRIMAQUINE 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
140<\/td>SODIUM VALPROATE & VALPROIC ACID CONTROLLED
\nRELEASE TABLETS<\/td>		EACH FILM COATED CONTROLLED RELEASE TABLET CONTAINS
\nSODIUM VALPROATE IP 200 MG
\nVALPROIC ACID IP 87 MG
\n(BOTH TOGETHER CORRESPONDS TO SODIUM VALPROATE 300 MG)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
141<\/td>PAROXETINE HYDROCHLORIDE
\nPROLONGED-RELEASE TABLETS IP 12.5 MG<\/td>		EACH FILM COATED PROLONGED-RELEASE TABLET CONTAINS
\nPAROXETINE HYDROCHLORIDE IP
\nEQ TO PAROXETINE 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
142<\/td>SODIUM VALPROATE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nSODIUM VALPROATE IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
143<\/td>ARIPIPRAZOLE TABLETS IP 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nARIPIPRAZOLE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, June 11, 2003<\/td><\/td>\n<\/tr>\n
144<\/td>POTASSIUM NITRATE, SODIUM MONOFLUOROPHOSPHATE
\nTRICLOSAN TOOTH PASTE
\n<\/td>		COMPOSITION
\nPOTASSIUM NITRATE BP 5.0% W\/W
\nSODIUM MONOFLUOROPHOSPHATE USP 0.7% W\/W
\nTRICLOSAN USP 0.3% W\/W
\nIN A PLEASANTLY FLAVOURED BASE Q.S.
\n(AVAILABLE FLUORIDE CONTENT 917 PPM WHEN PACKED)
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
145<\/td>FLUNARIZINE TABLETS IP 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nFLUNARIZINE DIHYDROCHLORIDE IP
\nEQ TO FLUNARIZINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1990-November <\/td><\/td>\n<\/tr>\n
146<\/td>SERTRALINE HYDROCHLORIDE TABLETS IP 50 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nSERTRALINE HYDROCHLORIDE IP
\nEQ TO SERTRALINE 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, June 09, 1998<\/td><\/td>\n<\/tr>\n
147<\/td>MIRTAZAPINE TABLETS IP 7.5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nMIRTAZAPINE IP 7.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
148<\/td>PROPRANOLOL HYDROCHLORIDE TABLETS IP 20 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nPROPRANOLOL HYDROCHLORIDE IP 20 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
149<\/td>SERTRALINE HYDROCHLORIDE TABLETS IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nSERTRALINE HYDROCHLORIDE IP
\nEQ TO SERTRALINE 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, June 09, 1998<\/td><\/td>\n<\/tr>\n
150<\/td>CHLORBUTOL, BENZOCAINE &
\nPARADICHLOROBENZENE EAR DROPS<\/td>		COMPOSITION
\nCHLORBUTOL IP 5.00% W\/W
\nBENZOCAINE IP 2.50% W\/W
\nPARADICHLOROBENZENE 2.00% W\/W
\nNON AQUEOUS BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
151<\/td>FLUNARIZINE TABLETS IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nFLUNARIZINE DIHYDROCHLORIDE IP
\nEQ.TO FLUNARIZINE 5 MG
\nEXCIPIENTS Q.S. <\/td>		IP<\/td>1990-November <\/td><\/td>\n<\/tr>\n
152<\/td>ARIPIPRAZOLE TABLETS IP 15 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nARIPIPRAZOLE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, June 11, 2003<\/td><\/td>\n<\/tr>\n
153<\/td>DESVENLAFAXINE SUCCINATE EXTENDED RELEASE TABLETS 50 MG<\/td>EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\nDESVENLAFAXINE SUCCINATE
\nEQ TO DESVENLAFAXINE 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, July 20, 2009<\/td><\/td>\n<\/tr>\n
154<\/td>QUETIAPINE TABLET IP 50 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nQUETIAPINE FUMARATE IP
\nEQ TO QUETIAPINE 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, June 03, 2002<\/td><\/td>\n<\/tr>\n
155<\/td>SALBUTAMOL & THEOPHYLLINE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nTHEOPHYLLINE (ANHYDROUS) IP 100 MG SALBUTAMOL SULPHATE IP
\nEQ. TO SALBUTAMOL 4 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
156<\/td>QUETIAPINE TABLETS IP 200 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nQUETIAPINE FUMARATE IP
\nEQ TO QUETIAPINE 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, June 03, 2002<\/td><\/td>\n<\/tr>\n
157<\/td>PERMETHRIN LOTION<\/td>COMPOSITION
\nPERMETHRIN 5 % W\/V
\nLOTION BASE Q.S.<\/td>		<\/td>Monday, March 06, 1995<\/td><\/td>\n<\/tr>\n
158<\/td>OXYMETAZOLINE HYDROCHLORIDE NASAL SOLUTION IP 0.05%W\/V<\/td>COMPOSITION
\nOXYMETAZOLINE HYDROCHLORIDE IP 0.05% W\/V
\nPRESERVATIVE
\nBENZALKONIUM CHLORIDE SOLUTION IP 0.01% W\/V
\nIN A BUFFERED AQUEOUS SOLUTION Q.S.<\/td>		IP<\/td>Wednesday, August 19, 2009<\/td><\/td>\n<\/tr>\n
159<\/td>ARIPIRAZOLE TABLETS IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nARIPIPRAZOLE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, February 23, 2004<\/td><\/td>\n<\/tr>\n
160<\/td>DULOXETINE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nDULOXETINE HYDROCHLORIDE IP
\nEQ TO DULOXETINE 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, November 02, 2004<\/td><\/td>\n<\/tr>\n
161<\/td>DIETHYLCARBAMAZINE CITRATE &
\nCHLORPHENIRAMINE MALEATE TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS
\nDIETHYLCARBAMAZINE CITRATE IP 150 MG
\n CHLORPHENIRAMINE MALEATE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
162<\/td>ARIPIPRAZOLE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nARIPIPRAZOLE IP 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, June 11, 2003<\/td><\/td>\n<\/tr>\n
163<\/td>LOSARTAN POTASSIUM
\n& HYDROCHLORTHIAZIDE TABLETS IP<\/td>		EACH FILM COATED TABLET CONTAINS
\nLOSARTAN POTASSIUM IP 25 MG
\nHYDROCHLORTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, May 31, 2013<\/td><\/td>\n<\/tr>\n
164<\/td>DOXEPIN HYDROCHLORIDE TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nDOXEPIN HYDROCHLORIDE IP
\nEQ TO DOXEPIN 25 MG
\n EXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>1972-September<\/td><\/td>\n<\/tr>\n
165<\/td>QUETIAPINE TABLET IP 100 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nQUETIAPINE FUMARATE IP
\nEQ TO QUETIAPINE 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, June 03, 2002<\/td><\/td>\n<\/tr>\n
166<\/td>LAMOTRIGINE DISPERSIBLE TABLETS IP 50 MG<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nLAMOTRIGINE IP 50 MG (IN A FLAVORED BASE)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, January 20, 2000<\/td><\/td>\n<\/tr>\n
167<\/td>IMIPRAMINE HYDROCHLORIDE TABLET IP<\/td>EACH FILM COATED TABLET CONTAINS
\nIMIPRAMINE HYDROCHLORIDE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>10,25 MG<\/td><\/td>\n<\/tr>\n
168<\/td>QUETIAPINE TABLET IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nQUETIAPINE FUMARATE IP
\nEQ TO QUETIAPINE 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, June 03, 2002<\/td><\/td>\n<\/tr>\n
169<\/td>DOMPERIDONE SUSPENSION IP<\/td>EACH ML CONTAINS
\nDOMPERIDONE IP 1 MG
\nIN FLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1978-November <\/td><\/td>\n<\/tr>\n
170<\/td>MICONAZOLE NITRATE &
\nFLUOCINOLONE ACETONIDE CREAM<\/td>		COMPOSITION
\nFLUOCINOLONE ACETONIDE IP 0.01% W\/W
\nMICONAZOLE NITRATE IP 2.0% W\/W
\nCREAM BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
171<\/td>DULOXETINE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nDULOXETINE HYDROCHLORIDE IP
\nEQ. TO DULOXETINE 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, November 02, 2004<\/td><\/td>\n<\/tr>\n
172<\/td>CLOMIPRAMINE HYDROCHLORIDE TABLETS 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nCLOMIPRAMINE HYDROCHLORIDE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>1992-Fabruary<\/td><\/td>\n<\/tr>\n
173<\/td>HALOPERIDOL DISPERSIBLE TABLET IP 5 MG. <\/td>EACH DISPERSIBLE UNCOATED TABLET CONTAINS
\nHALOPERIDOL IP 5 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
174<\/td>DIPHENOXYLATE HYDROCHLORIDE & ATROPINE SULPHATE IP <\/td>EACH UNCOATED TABLET CONTAINS
\nDIPHENOXYLATE HYDROCHLORIDE IP 2.5 MG
\nATROPINE SULPHATE IP 0.025 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>1969-June<\/td><\/td>\n<\/tr>\n
175<\/td>CARISOPRODOL TABLETS IP 350 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nCARISOPRODOL IP 350 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Monday, March 01, 1965<\/td><\/td>\n<\/tr>\n
176<\/td>LEFLUNOMIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEFLUNOMIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, October 01, 2001<\/td><\/td>\n<\/tr>\n
177<\/td>GLIMEPIRIDE TABLETS IP 2 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nGLIMEPIRIDE IP 2 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Sunday, January 24, 1999<\/td><\/td>\n<\/tr>\n
178<\/td>DICYCLOMINE HYDROCHLORIDE
\n& SIMETHICONE SUSPENSION<\/td>		EACH ML CONTAINS
\nDICYCLOMINE HYDROCHLORIDE IP 10 MG
\nSIMETHICONE IP 40 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
179<\/td>DOXEPIN HYDROCHLORIDE TABLETS 75 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nDOXEPINE HYDROCHLORIDE IP
\nEQ TO DOXEPIN 75 MG
\n EXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
180<\/td>HALOPERIDOL TABLET IP <\/td>EACH UNCOATED TABLET CONTAINS
\nHALOPERIDOL IP 1.5 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
181<\/td>DIPHENHYDRAMINE HYDROCHLORIDE,
\nAMMONIUM CHLORIDE, SODIUM CITRATE & MENTHOL SYRUP<\/td>		EACH 5 ML CONTAINS
\nDIPHENHYDRAMINE HYDROCHLORIDE IP 14.08 MG
\nAMMONIUM CHLORIDE IP 138 MG
\nSODIUM CITRATE IP 100 MG
\nMENTHOL IP 1.14 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
182<\/td>THYMOL, MENTHOL, ICHTHAMMOL
\n& LIGNOCAINE HCl OINTMENT<\/td>		COMPOSITION
\nTHYMOL IP 0.50%W\/W
\nMENTHOL IP 0.20%W\/W
\nICHTHAMMOL BP 1.00%W\/W
\nLIGNOCAINE HYDROCHLORIDE IP 1.00%W\/W
\nIN OINTMENT BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
183<\/td>PERMETHRIN CREAM <\/td>EACH GM CREAM CONTAINS
\nPERMETHRIN 50 MG
\nCREAM BASE Q.S.<\/td>		<\/td>Monday, March 06, 1995<\/td><\/td>\n<\/tr>\n
184<\/td>CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN
\nHYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE SYRUP<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 10 MG
\nPHENYLEPHRINE
\nHYDROCHLORIDE IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
185<\/td>IMIPRAMINE HYDROCHLORIDE TABLET IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nIMIPRAMINE HYDROCHLORIDE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
186<\/td>DICLOFENAC DIETHYLAMINE, LINSEED OIL, MENTHOL & METHYL SALICYLATE GEL
\n <\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ. TO DICLOFENAC SODIUM 1.00% W\/W
\nLINSEED OIL BP 3.000 % W\/W
\nMENTHOL IP 0.50% W\/W
\nMETHYL SALICYLATE IP 10.000% W\/W
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
187<\/td>CLOMIPRAMINE HYDROCHLORIDE TABLETS 50 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nCLOMIPRAMINE HYDROCHLORIDE IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>1992-Fabruary<\/td><\/td>\n<\/tr>\n
188<\/td>TACROLIMUS OINTMENT <\/td>COMPOSITION
\nTACROLIMUS IP 0.03 % W\/W
\nOINTMENT BASE Q.S.<\/td>		<\/td>Friday, March 07, 2003<\/td><\/td>\n<\/tr>\n
189<\/td>LAMOTRIGINE DISPERSIBLE TABLETS IP<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nLAMOTRIGINE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, April 05, 2010<\/td><\/td>\n<\/tr>\n
190<\/td>ACECLOFENAC & THIOCOLCHICOSIDE TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nTHIOCOLCHICOSIDE IP 8 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOURED USED<\/td>		<\/td>Monday, August 03, 2009<\/td><\/td>\n<\/tr>\n
191<\/td>TOPIRAMATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nTOPIRAMATE IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, August 23, 1999<\/td><\/td>\n<\/tr>\n
192<\/td>OLANZAPINE MOUTH DISSOLVING TABLETS 10 MG<\/td>EACH UNCOATED MOUTH DISSOLVING TABLET CONTAINS
\nOLANZAPINE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, January 27, 2000<\/td><\/td>\n<\/tr>\n
193<\/td>GAMMABENZENE HEXACHLORIDE &
\n CETRIMIDE LOTION<\/td>		COMPOSITION
\nGAMMABENZENE HEXACHLORIDE IP 1.0 % W\/V
\nCETRIMIDE IP 0.06% W\/V
\nIN EMULSION BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
194<\/td>GAMMABENZENE HEXACHLORIDE LOTION<\/td>COMPOSITION
\nGAMMA BENZENE HEXACHLORIDE IP 1.0 % W\/V
\nIN AQUEOUS BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
195<\/td>SPARFLOXACIN TABLETS 200 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nSPARFLOXACIN 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, November 11, 1996<\/td><\/td>\n<\/tr>\n
196<\/td>POTASSIUM CITRATE MONOHYDRATE, CITRIC ACID MONOHYDRATE SOLUTION BP<\/td>EACH 5 ML CONTAINS
\nPOTASSIUM CITRATE MONOHYDRATE IP 1100 MG
\nCITRIC ACID MONOHYDRATE IP 334 MG
\nFLAVOURED BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		U.S.P<\/td><\/td><\/td>\n<\/tr>\n
197<\/td>VENLAFAXINE HYDROCHLORIDE EXTEND RELEASE TABLETS <\/td>EACH UNCOATED EXTENDE RELEASE TABLET CONTAINS
\nVENLAFAXINE HYDROCHLORIDE BP
\nEQ TO VENLAFAXINE 75 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>Monday, September 18, 2000<\/td><\/td>\n<\/tr>\n
198<\/td>TACROLIMUS OINTMENT <\/td>COMPOSITION
\nTACROLIMUS IP 0.01 % W\/W
\nOINTMENT BASE Q.S.<\/td>		<\/td>Friday, March 07, 2003<\/td><\/td>\n<\/tr>\n
199<\/td> LIGNOCAINE HYDROCHLORIDE GEL IP<\/td>COMPOSITION
\nLIGNOCAINE HYDROCHLORIDE IP 2.00%W\/W
\nMETHYL PARABEN IP 0.061%W\/W
\nPROPYL PARABEN IP 0.027%W\/W
\nIN A WATER SOLUBLE GEL BASE Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
200<\/td>LEVAMISOLE TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS
\nLEVAMISOLE HYDROCHLORIDE IP
\nEQ TO LEVAMISOLE 50 MG
\nEXCIPIENTS Q.S. APPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
201<\/td> PARACETAMOL & ETODOLAC TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nETODOLAC IP 400 MG
\nPARACETAMOL IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Friday, October 01, 2010<\/td><\/td>\n<\/tr>\n
202<\/td>ISOSORBIDE MONONITRATE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nDILUTED ISOSORBIDE MONONITRATE IP
\nEQ TO ISOSORBIDE 20 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>1985-August <\/td><\/td>\n<\/tr>\n
203<\/td>HYDROXYZINE HYDROCHLORIDE TABLETS IP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nHYDROXYZINE HYDROCHLORIDE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
204<\/td>UREA, LACTIC ACID, PROPYLENE GLYCOL & LIQUID PARAFFIN CREAM <\/td>COMPOSITION
\nUREA IP 10.0%W\/W
\nLACTIC ACID IP 10.0%W\/W
\nPROPYLENE GLYCOL IP 10.0%W\/W
\nLIQUID PARFAFFIN IP 10.0%W\/W
\nIN ACREAML BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
205<\/td>MINOCYCLINE TABLETS BP<\/td>EACH UNCOATED TABLET CONTAINS
\nMINOCYCLINE HYDROCHLORIDE BP
\nEQ TO MINOCYCLINE 100 MG
\nEXCIPIENTS Q.S.<\/td>		BP<\/td>1988-May<\/td><\/td>\n<\/tr>\n
206<\/td>LACTULOSE SOLUTION BP<\/td>EACH 5ML CONTAINS
\nLACTULOSE CONCENTRATE BP
\nEQ. TO LACTULOSE 3.335 GM
\nFLAVOURED SYRUP BASE Q.S.<\/td>		BP<\/td><\/td><\/td>\n<\/tr>\n
207<\/td>DEXAMETHASONE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nDEXAMETHASONE IP 0.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
208<\/td> IBUPROFEN & PARACETAMOL TABLETS IP<\/td>EACH FILM COATED TABLET CONTAIN
\nIBUPROFEN IP 400 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1984-October<\/td><\/td>\n<\/tr>\n
209<\/td>SULFASALAZINE DELAYED RELEASE TABLETS BP 500 MG<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nSULFASALAZINE BP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		BP<\/td><\/td><\/td>\n<\/tr>\n
210<\/td>BUDESONIDE CAPSULES<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nBUDESONIDE IP 3 MG
\n (AS CONTROLLED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULES SHELLS & PELLETS
\n<\/td>		<\/td>Tuesday, June 17, 2008<\/td><\/td>\n<\/tr>\n
211<\/td>BISACODYL TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nBISACODYL IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
212<\/td>HYDROXYCHLOROQUINE SULPHATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nHYDROXYCHLOROQUINE SULPHATE IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
213<\/td>TRIOXSALEN TABLETS BP 25 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nTRIOXSALEN BP 25 MG
\nEXCIPIENT Q.S.
\nAPPROVED COLOUR USED<\/td>		BP<\/td><\/td><\/td>\n<\/tr>\n
214<\/td>CHLORPHENIRAMINE MALEATE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCHLORPHENIRAMINE MALEATE IP 4 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
215<\/td>ETOFYLLINE, BROMHEXINE HYDROCHLORIDE
\n & SALBUTAMOL SULPHATE TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nSALBUTAMOL SULPHATE IP
\nEQ TO SALBUTAMOL 4 MG
\nETOPHYLLINE (ANHYDROUS) BP 200 MG
\nBROMHEXINE HYDROCHLORIDE IP 16 MG
\nEXCIPIENTS Q.S. APPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
216<\/td>LEVETIRACETAM TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVETIRACETAM IP 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, April 05, 2005<\/td><\/td>\n<\/tr>\n
217<\/td>LEVETIRACETAM TABLES IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVETIRACETAM IP 1000 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>2005-May<\/td><\/td>\n<\/tr>\n
218<\/td>LOSARTAN POTASSIUM TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLOSARTAN POTTASIUM IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		IP<\/td>Tuesday, June 16, 1998<\/td><\/td>\n<\/tr>\n
219<\/td>DICLOFENAC DIETHYLAMINE, LINSEED OIL,MENTHOL , METHYL
\nSALICYLATE & BENZYL ALCOHOL GEL<\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ TO DICLOFENAC SODIUM 1.000% W\/W
\nLINSEED OIL BP 3.00% W\/W
\nMENTHOL IP 5.00% W\/W
\nMETHYL SALICYLATE IP 10.00% W\/W
\nBENZYL ALCOHOL IP 1.0 % W\/W
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
220<\/td>URSODEOXYCHOLIC ACID IP TABLETS 150 MG<\/td>EACH UNCOATED TABLET CONATINS
\nURSODEOXYCHOLIC ACID IP 150 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
221<\/td>TRAZODONE HYDROCHLORIDE TABLETS BP <\/td>EACH UNCOATED TABLET CONTAINS
\nTRAZODONE HYDROCHLORIDE BP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		U.S.P<\/td><\/td><\/td>\n<\/tr>\n
222<\/td>HALOPERIDOL TABLET IP <\/td>EACH UNCOATED TABLET CONTAINS
\nHALOPERIDOL IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
223<\/td>PRAMIPEXOLE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nPRAMIPEXOLE
\nDIHYDROCHLORIDE MONOHYDRATE BP 0.5 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>Monday, July 25, 2005<\/td><\/td>\n<\/tr>\n
224<\/td>DULOXETINE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONATINS
\nDULOXETINE HYDROCHLORIDE IP
\nEQ TO DULOXETINE 40 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, November 02, 2004<\/td><\/td>\n<\/tr>\n
225<\/td>DICLOFENAC DIETHYLAMINE, LINSEED OIL, MENTHOL,
\n METHYL SALICYLATE & BENZYL ALCOHOL GEL<\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 2.30%W\/W
\nEQ TO DICLOFENAC SODIUM 2.00%W\/W
\nLINSEED OIL BP 3.00%W\/W
\nMENTHOL IP 5.0%W\/W
\nMETHYL SALICYLATE IP 10.0%W\/W
\nBENZYL ALCOHOL IP 1.0% W\/W
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
226<\/td>DEXTROMETHORPHAN TABLET 20 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nDEXTROMETHORPHAN
\nHYDROBROMIDE IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
227<\/td>DEXTROMETHORPHAN TABLET 30 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nDEXTROMETHORPHAN
\nHYDROBROMIDE IP 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
228<\/td>NEOMYCIN, BECLOMETHASONE , CLOTRIMAZOLE
\n& LIGNOCAINE EAR DROPS<\/td>		COMPOSITION
\nBECLOMETHASONE DIPROPIONATE IP 0.025% W\/V
\nCLOTRIMAZOLE IP 1.0% W\/V
\nLIGNOCAINE HYDROCHLORIDE IP 2.0% W\/V
\nNEOMYCIN SULPHATE IP 0.5% W\/V
\nIN AQUES BASE SOLUTION Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
229<\/td>ISOTRETINOIN CAPSULES IP 20 MG<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nISOTRETINOIN IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULE SHELLS<\/td>		IP<\/td>Friday, June 21, 2002<\/td><\/td>\n<\/tr>\n
230<\/td>OFLOXACIN TABLETS IP 200 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nOFLOXACIN IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
231<\/td>PARACETAMOL & DROTAVERINE HYDROCHLORIDE TABLETS<\/td>EACH FILM COATED TABLET CONTAIN
\nDROTAVERINE HYDROCHLORIDE IP 80 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
232<\/td>DICLOFENAC DIETHYLAMINE, LINSEED OIL,MENTHOL , METHYL
\nSALICYLATE & CAPSAICIN GEL<\/td>		COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ TO DICLOFENAC SODIUM 1.00% W\/W
\nLINSEED OIL BP 3.00% W\/W
\nMENTHOL IP 5.00% W\/W
\nMETHYL SALICYLATE IP 10.00% W\/W
\nCAPSAICIN USP 0.025%W\/W
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
233<\/td>AMLODIPINE & TELMISARTAN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nAMLODIPINE BESYLATE IP EQ TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
234<\/td>LINEZOLID TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nLINEZOLID IP 600 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Sunday, May 30, 2004<\/td><\/td>\n<\/tr>\n
235<\/td>PARACETAMOL & CAFFEINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 650 MG
\nCAFFEINE ANHYDROUS IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
236<\/td>DICLOFENAC SODIUM SR TABLETS IP<\/td>EACH FILM COATED SUSTAINED RELEASE TABLET CONTAINS
\nDICLOFENC SODIUM IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1988-January <\/td><\/td>\n<\/tr>\n
237<\/td>HYDROXYZINE HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nHYDROXYZINE HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
238<\/td>SILDENAFIL CITRATE TABLETS BP
\n
\n(FOR EXPORT)<\/td>		EACH FILM COATED TABLET CONTAINS
\nSILDENAFIL CITRATE BP
\nEQ.TO SILDENAFIL 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, January 08, 2001<\/td><\/td>\n<\/tr>\n
239<\/td>ATORVASTATIN TABLETS IP 10 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nATORVASTATIN CALCIUM IP
\nEQ TO ATORVASTATIN 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, September 17, 1999<\/td><\/td>\n<\/tr>\n
240<\/td>ROSUVASTATIN CALCIUM TABLETS IP
\n<\/td>		EACH FILM COATED TABLET. CONTAINS
\nROSUVASTATIN CALCIUM
\nEQ.TO ROSUVASTATIN 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Saturday, November 08, 2008<\/td><\/td>\n<\/tr>\n
241<\/td>NORFLOXACIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nNORFLOXACIN IP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>1987-November <\/td><\/td>\n<\/tr>\n
242<\/td>NIMESULIDE TABLETS 100 MG<\/td>EACH UNCOATED TABLETS CONTAINS
\nNIMESULIDE BP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Friday, January 13, 1995<\/td><\/td>\n<\/tr>\n
243<\/td>NORFLOXACIN & TINIDAZOLE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nNORFLOXACIN IP 400 MG
\nTINIDAZOLE IP 600 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Tuesday, May 09, 1995<\/td><\/td>\n<\/tr>\n
244<\/td>TADALAFIL TABLETS IP 20 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nTADALAFIL IP 20 MG EXCIPINTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, September 11, 2003<\/td><\/td>\n<\/tr>\n
245<\/td>SILVER SULFADIAZINE, LIGNOCAINE HYDROCHLORIDE & CHLORHEXIDINE GLUCONATE CREAM <\/td>COMPOSITION
\nSILVER SULFADIAZINE IP 1.00 % W\/W
\nLIGNOCAINE HYDROCHLORIDE IP 2.00 % W\/W
\nCHLORHEXIDINE GLUCONATE SOLUTION IP
\nEQ. TO CHLORHEXIDINE GLUCONATE 0.20 % W\/W
\nCREAM BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
246<\/td>DEXTROMETHORPHAN HYDROBROMIDE & CHLORPHENIRAMINE MALEATE SYRUP<\/td>EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 10 MG CHLORPHENIRAMINE MALEATE IP 4 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
247<\/td>AMLODIPINE & LOSARTAN POTASSIUM TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ TO AMLODIPINE 5 MG
\nLOSARTAN POTASSIUM IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
248<\/td>CHLORBUTOL, BENZOCAINE &
\nPARADICHLOROBENZENE EAR DROPS<\/td>		COMPOSITION
\nCHLORBUTOL IP 5.00% W\/V
\nBENZOCAINE IP 2.50% W\/V
\nPARADICHLOROBENZENE 2.00% W\/V
\nNON AQUEOUS BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
249<\/td>CETIRIZINE TABLETS BP
\n (FOR EXPORT)<\/td>		EACH FILM COATED TABLET CONTAINS
\nCETIRIZINE DIHYDROCHLORIDE BP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
250<\/td>MIRTAZAPINE TABLETS IP 15 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nMIRTAZAPINE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Tuesday, February 13, 2001<\/td><\/td>\n<\/tr>\n
251<\/td>ATORVASTATIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nATORVASTATIN CALCIUM IP
\nEQ TO ATORVASTATIN 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, September 17, 1999<\/td><\/td>\n<\/tr>\n
252<\/td>PARACETAMOL DROPS<\/td>EACH ML CONTAINS
\nPARACETAMOL IP 150 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
253<\/td>BROMHEXINE HYDROCHLORIDE, GUAIPHENESIN
\n & TERBUTALINE SULPHATE SYRUP<\/td>
\nEACH 5 ML CONTAINS
\nBROMHEXINE HYDROCHLORIDE IP 2.0 MG
\nTERBUTALINE SULPHATE IP 2.5 MG
\nGUAIPHENESIN IP 100 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
254<\/td>OMEPRAZOLE MAGNESIUM & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nOMEPRAZOLE MAGNESIUM BP
\nEQ TO OMEPRAZOLE 10 MG
\nDOMPERIDONE IP 15 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
255<\/td>OMEPRAZOLE MAGNESIUM & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nOMEPRAZOLE MAGNESIUM BP
\nEQ TO OMEPRAZOLE 10 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
256<\/td>THYMOL, MENTHOL, ICHTHAMMOL
\n& LIGNOCAINE HCl OINTMENT<\/td>		COMPOSITION
\nTHYMOL IP 0.50%W\/W
\nMENTHOL IP 1.0%W\/W
\nICHTHAMMOL BP 0.20%W\/W
\nLIGNOCAINE HYDROCHLORIDE IP 1.00%W\/W
\nIN OINTMENT BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
257<\/td>VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS <\/td>EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nVENLAFAXINE HYDROCHLORIDE IP
\nEQ TO VENLAFAXINE 75 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td>Monday, September 18, 2000<\/td><\/td>\n<\/tr>\n
258<\/td>PHENYLEPHRINE HYDROCHLORIDE, PARACETAMOL &
\nCHLORPHENIRAMINE MALEATE DROP<\/td>		EACH ML CONTAINS
\nPHENYLEPHRINE HYDROCHLORIDE IP 2.5 MG
\nPARACETAMOL IP 125 MG
\nCHLORPHENIRAMINE MALEATE IP 1 MG
\nIN A FLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
259<\/td>PRAZIQUANTEL TABLETS BP<\/td>EACH UNCOATED TABLET CONTAINS
\nPRAZIQUANTEL BP 600 MG
\nEXCIPIENTS Q.S.<\/td>		U.S.P<\/td>1985-August <\/td><\/td>\n<\/tr>\n
260<\/td>ILAPRAZOLE & DOMPERIDONE CAPSULES<\/td>COMPOSITION
\nEACH HARD GELATIN CAPSULE CONTAINS
\nILAPRAZOLE IP 10 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELLS<\/td>		<\/td>Wednesday, May 04, 2022<\/td><\/td>\n<\/tr>\n
261<\/td>FEXOFENADINE HYDROCHLORIDE TABLETS IP 180 mg<\/td>EACH FILM COATED TABLET CONTAINS
\nFEXOFENADINE HYDROCHLORIDE IP 180 mg
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>16\/09\/1998
\n<\/td>		<\/td>\n<\/tr>\n
262<\/td>TERBUTALINE SULPHATE, BROMHEXINE HYDROCHLORIDE, GUAIPHENESIN & MENTHOL SYRUP<\/td>EACH 5 ML CONTAINS
\nBROMHEXINE HYDROCHLORIDE IP 4 mg
\nTERBUTALINE SULPHATE IP 2.50 mg
\nGUAIPHENESIN IP 100 mg
\nMENTHOL IP 0.5 mg
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
263<\/td>LEVOCETIRIZINE DIHYDROCHLORIDE SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nLEVOCETIRIZINE DIHYDROCHLORIDE IP 2.5 mg
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td>Saturday, September 29, 2007<\/td><\/td>\n<\/tr>\n
264<\/td>ACECLOFENAC SUSTAINED RELEASE AND ENTERIC COATED RABEPRAZOLE SODIUM CAPSULES<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nACECLOFENAC IP 200 MG
\n(AS SUSTAINED RELEASE PELLETS )
\nRABEPRAZOLE SODIUM IP 20 MG
\n(AS ENTERIC COATED PELLETS )
\nEXCIPIENTS Q.S.
\nCOLOUR APPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
265<\/td>ZONISAMIDE CAPSULES USP 100 MG<\/td>COMPOSITION
\nEACH HARD GELATIN CAPSULE CONTAINS
\nZONISAMIDE IP 100 MG
\nAPPROVED COLOUR USED IN CAPSULE SHELLS.<\/td>		<\/td>Wednesday, December 21, 2005<\/td><\/td>\n<\/tr>\n
266<\/td>RABEPRAZOLE GASRTO-RESISTANT AND DOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, October 04, 2004<\/td><\/td>\n<\/tr>\n
267<\/td>ESOMEPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQUIVALENT TO
\nESOMEPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Monday, June 26, 1905<\/td><\/td>\n<\/tr>\n
268<\/td>PANTOPRAZOLE (EC) & LEVOSULPIRIDE (SR) CAPSULES <\/td>EACH HARD GELATIN CAPSULES CONTAINS
\nPANTOPRAZOLE SODIUM SESQUIHYDRATE IP
\nEQUIVALENT TO
\nPANTOPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nLEVOSULPIRIDE 75 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		 <\/td><\/td><\/td>\n<\/tr>\n
269<\/td>RABEPRAZOLE SODIUM (EC) AND LEVOSULPIRIDE (SR) CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nLEVOSULPIRIDE 75 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Friday, August 19, 2011<\/td><\/td>\n<\/tr>\n
270<\/td>PARACETAMOL, PHENYLEPHRINE HCL, CHLORPHENIRAMINE MALEATE,
\nSODIUM CITRATE AND MENTHOL SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS -
\nPARACETAMOL IP 250 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG CHLORPHENIRAMINE MALEATE IP 2 MG
\nSODIUM CITRATE IP 60 MG
\nMENTHOL IP 1 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
271<\/td>CYPROHEPTADINE HYDROCHLORIDE & TRICHOLINE CITRATE SYRUP<\/td>EACH 5 ML CONTAINS
\nCYPROHEPTADINE HCL IP 2 MG
\nTRICHOLINE CITRATE 275 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
272<\/td>TERBUTALINE SULPHATE, GUAIPHENESIN, BROMHEXINE
\nHCl &MENTHOL SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nTERBUTALINE SULPHATE IP 1.25 MG
\nGUAIPHENESIN IP 50 MG
\nBROMHEXINE HCl IP 4 MG
\nMENTHOL IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
273<\/td> LEVOSALBUTAMOL SULPHATE, AMBROXOL HCL & GUAIPHENESIN SYRUP <\/td>EACH 5 ML CONTAINS
\nLEVOSALBUTAMOL SULPHATE IP
\nEQUIVALENT TO
\nLEVOSALBUTAMOL 1 MG
\nAMBROXOL HCL IP 30 MG
\nGUAIPHENESIN IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td>Thursday, March 19, 2009<\/td><\/td>\n<\/tr>\n
274<\/td>PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE & CHLORPHENIRAMINE MALEATE TABLETS<\/td>EACH UNCOATED TABLETS CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 10 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
275<\/td>AMBROXOL HYDROCHLORIDE, DEXTROMETHORPHAN HBr, CETIRIZINE & MENTHOL SYRUP<\/td>EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG DEXTROMETHORPHAN HBr IP 10 MG
\nCETIRIZINE DIHYDROCHLORIDE IP 5 MG
\nMENTHOL IP 0.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
276<\/td>CALCIUM CITRATE, MAGNESIUM, ZINC & VITAMIN D3TABLETS<\/td>EACH FILM COATED TABLET CONTAINS -
\nCALCIUM CITRATE USP 1000 MG
\nMAGNESIUM HYDROXIDE IP
\nEQUIVALENT TO
\nELEMENTAL MAGNESIUM 100 MG
\nZINC SULPHATE MONOHYDRATE IP
\nEQUIVALENT TO
\nELEMENTEL ZINC 4 MG
\nVITAMIN D3 IP 200 IU
\nEXCIPIENTS Q.S
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
277<\/td>DRIED ALUMINIUM HYDROXIDE GEL, MAGNESIUM HYDROXIDE AND SIMETHICONE SUSPENSION<\/td>EACH 5 ML CONTAINS
\nDRIED ALUMINIUM HYDROXIDE GEL IP 250 MG
\nMAGNESIUM HYDROXIDE IP 250 MG
\n SIMETHICONE IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
278<\/td>LEVOFLOXACIN & ORNIDAZOLE TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVOFLOXACIN HEMIHYDRATE IP EQUIVALENT TO
\nLEVOFLOXACIN 250 MG
\nORNIDAZOLE IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Friday, July 23, 1999<\/td><\/td>\n<\/tr>\n
279<\/td>MILK OF MAGNESIA LIQUID PARAFFIN AND
\nSODIUM PICOSULFATE SUSPENSION
\n<\/td>		EACH 5ML CONTAINS -
\n LIQUID PARAFFIN IP 1.25 ML
\nMILK OF MAGNESIA IP 3.75 ML
\nSODIUM PICOSULFATE BP 3.33 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
280<\/td>PARACETAMOL & MEFENAMIC ACID SUSPENSION<\/td>EACH 5 ML CONTAINS -
\nPARACETAMOL IP 250 MG
\nMEFENAMIC ACID IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
281<\/td>MEFENAMIC ACID & PARACETAMOL SUSPENSION<\/td>EACH 5ML CONTAINS -
\nPARACETAMOL IP 125 MG
\nMEFENAMIC ACID IP 50.0 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
282<\/td>PARACETAMOL, CHLORPHENIRAMINE
\nMALEATE AND
\nPHENYLEPHRINE HYDROCHLORIDE
\nSUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nPARACETAMOL IP 250 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nPHENYLEPHRINE HCI IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
283<\/td>PHENYLEPHRINE HYDROCHLORIDE AND
\nCHLORPHENIRAMINE
\nMALEATE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
284<\/td>TRANEXAMIC ACID & MEFENAMIC ACID TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nTRANEXAMIC ACID IP 500 MG
\nMEFENAMIC ACID IP 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Tuesday, February 22, 2005<\/td><\/td>\n<\/tr>\n
285<\/td>PANTOPRAZOLE & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQUIVALENT. TO
\n PANTOPRAZOLE 20 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
286<\/td>AMBROXOL HYDROCHLORIDE, GUAIPHENESIN AND TERBUTALINE SULPHATE SYRUP<\/td>EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG
\nGUAIPHENESIN IP 50 MG
\nTERBUTALINE SULPHATE IP 1.25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
287<\/td>MONTELUKAST SODIUM &
\nLEVOCETIRIZINE HCL DISPERSIBLE TABLETS
\n<\/td>		EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nMONTELUKAST SODIUM IP
\nEQUIVALENT TO
\n MONTELUKAST 4 MG
\nLEVOCETIRIZINE HYDROCHLORIDE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
288<\/td>AMBROXOL HYDROCHLORIDE,
\nLEVOSALBUTAMOL AND GUAIPHENESIN SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG
\nLEVOSALBUTAMOL SULPHATE IP
\nEQUIVALENT TO
\n LEVOSALBUTAMOL 0.5 MG
\nGUAIPHENESIN IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
289<\/td>DEXTROMETHORPHAN HBr, PHENYLEPHRINE HYDROCHLORIDE AND
\nCHLORPHENIRAMINE MALEATE SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 15 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
290<\/td>ITRACONAZOLE CAPSULES B.P<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nITRACONAZOLE PELLETS
\nEQUIVALENT TO
\nITRACONAZOLE BP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN THE CAPSULE SHELLS<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
291<\/td>OMEPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE CAPSULES IP <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nOMEPRAZOLE IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
292<\/td>SUCRALFATE &
\nOXETACAINE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nSUCRALFATE IP 1 G
\nOXETACAINE BP 20 MG
\nFLAVOURED SYRUPY BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
293<\/td>DEXTROMETHORPHAN HYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE AND
\nCHLORPHENIRAMINE MALEATE SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 10 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
294<\/td>PARACETAMOL, PHENYLEPHRINE HCL &
\nCHLORPHENIRAMINE MALEATE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nPARACETAMOL IP 125 MG
\nPHENYLEPHRINE HCL IP 2.5 MG
\nCHLORPHENIRAMINE MALEATE IP 1 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
295<\/td>PARACETAMOL ORAL SUSPENSION IP<\/td>EACH 5 ML CONTAINS
\nPARACETAMOL IP 250 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
296<\/td>PANTOPRAZOLE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQ. TO PANTOPRAZOLE 40 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Friday, May 20, 2005<\/td><\/td>\n<\/tr>\n
297<\/td>LEVOCETIRIZINE DIHYDROCHLORIDE WITH
\nMONTELUKAST SODIUM SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nLEVOCETIRIZINE DIHYDROCHLORIDE 2.5 MG
\nMONTELUKAST SODIUM IP
\nEQ. TO MONTELUKAST 4 MG
\nIN A FLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
298<\/td>AMBROXOL HCL, TERBUTALINE, GUAIPHENESIN AND
\nMENTHOL SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE 15 MG
\nTERBUTALINE SULPHATE IP 1.25 MG
\nGUAIPHENESIN IP 50 MG
\nMENTHOL IP 2.5 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Wednesday, March 26, 2008<\/td><\/td>\n<\/tr>\n
299<\/td>ONDANSETRON ORAL SOLUTION IP<\/td>EACH 5 ML CONTAINS
\nONDANSETRON HYDROCHLORIDE IP
\nEQUIVALENT TO
\nONDANSETRON 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
300<\/td>ACECLOFENAC & PARACETAMOL TABLETS 100\/325 MG<\/td>EACH UNCOATED BILAYERED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
301<\/td>RABEPRAZOLE GASTRO-RESISTANT TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\nEXCEIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Thursday, December 27, 2001<\/td><\/td>\n<\/tr>\n
302<\/td>DOXYLAMINE SUCCINATE 10 MG, PYRIDOXINE HYDROCHLORIDE 10 MG & FOLIC ACID 2.5 MG TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nDOXYLAMINE SUCCINATE BP 10 MG
\nPYRIDOXINE HYDROCHLORIDE IP 10 MG
\nFOLIC ACID IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
303<\/td>LACTULOSE SOLUTION USP<\/td>EACH 15 ML CONTAINS
\nLACTULOSE SOLUTION BP
\nEQUIVALENT TO
\nLACTULOSE 10 GM
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		USP<\/td>Thursday, February 08, 2007<\/td><\/td>\n<\/tr>\n
304<\/td>FERROUS ASCORBATE & FOLIC ACID SYRUP<\/td>EACH 5 ML CONTAINS
\nFERROUS ASCORBATE
\nEQUIVALENT TO
\nELEMENTAL IRON 30 MG
\nFOLIC ACID IP 550 MCG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
305<\/td>CALCIUM CARBONATE & VITAMIN D3 TABLETS <\/td>EACH FILM-COATED TABLET CONTAINS
\nCALCIUM CARBONATE IP 1250 MG
\n(FROM AN ORGANIC SOURCE OYSTER SHELL)
\nEQUIVALENT TO
\nELEMENTAL CALCIUM 500 MG
\nVITAMIN D3 IP 250 IU
\n EXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
306<\/td>CALCIUM CITRATE, VITAMIN D3, MAGNESIUM & ZINC TABLETS<\/td>EACH FILM-COATED TABLET CONTAINS
\nCALCIUM CITRATE USP 1000 MG
\nMAGNESIUM HYDROXIDE IP
\nEQUIVALENT TO
\nELEMENTAL MAGNESIUM 100 MG
\nZINC SULPHATE MONOHYDRATE IP
\nEQUIVALENT TO
\nELEMENTAL ZINC 4 MG
\nVITAMIN D3 IP 1000 IU
\n EXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
307<\/td>CALCIUM CITRATE, CALCITRIOL & ZINC TABLETS <\/td>EACH FILM-COATED TABLET CONTAINS
\nCALCIUM CITRATE USP 1000 MG
\nCALCITRIOL IP 0.25 MG
\nZINC SULPHATE MONOHYDRATE IP
\nEQUIVALENT TO
\nELEMENTAL ZINC 4 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
308<\/td>DEFLAZACORT TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nDEFLAZACORT 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
309<\/td>FEXOFENADINE HYDROCHLORIDE & MONTELUKAST TABLETS<\/td>EACH FILM-COATED TABLET CONTAINS
\nFEXOFENADINE HYDROCHLORIDE IP 180 MG
\nMONTELUKAST SODIUM IP
\nEQUIVALENT TO
\nMONTELUKAST 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
310<\/td>METFORMIN PROLONGED RELEASE AND
\nGLIMEPIRIDE TABLETS IP
\n<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HCL IP 500 MG
\n(IN PROLONGED-RELEASE FROM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Wednesday, November 13, 2002<\/td><\/td>\n<\/tr>\n
311<\/td>PIRACETAM TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nPIRACETAM IP 800 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
312<\/td>RABEPRAZOLE SODIUM & DOMPERIDONE TABLETS<\/td>EACH ENTERIC-COATED TABLET CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
313<\/td>ITRACONAZOLE CAPSULES BP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nITRACONAZOLE PELLETS
\nEQUIVALENT TO
\nITRACONAZOLE BP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN THE CAPSULE SHELLS<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
314<\/td>OXCARBAMEZEPINE TABLETS IP 600 MG<\/td>EACH FILM -COATED TABLET CONTAINS
\nOXCARBAMAZEPINE IP 600 MG
\nEXCIPENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
315<\/td>DEFLAZACORT TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nDEFLAZACORT 6 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
316<\/td>CLOTRIMAZOLE VAGINAL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nCLOTRIMAZOLE IP 100 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td>Tuesday, February 17, 1998<\/td><\/td>\n<\/tr>\n
317<\/td>DICLOFENAC DIETHYLAMINE, MENTHOL, METHYL SALICYLATE, LINSEED OIL & THIOCOLCHICOSIDE GEL<\/td>COMPOSITION
\nDICLOFENAC DIETHYLAMINE IP 1.16% W\/W
\nEQ. TO DICLOFENAC SODIUM 1.00% W\/W
\nMENTHOL IP 5.00% W\/W
\nMETHYL SALICYLATE IP 10.00% W\/W
\nLINSEED OIL BP 3.00% W\/W
\nTHIOCOLCHICOSIDE IP 0.125% W\/W
\nGEL BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
318<\/td>ITRACONAZOLE CAPSULES BP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nITRACONAZOLE PELLETS
\nEQUIVALENT TO
\nITRACONAZOLE BP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN THE CAPSULE SHELLS<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
319<\/td>METHYLDOPA TABLETS IP 500 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nMETHYLDOPA IP
\nEQUIVALENT TO ANHYDROUS METHYLDOPA 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
320<\/td>METHYLDOPA TABLETS IP 250 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nMETHYLDOPA IP
\nEQUIVALENT TO ANHYDROUS METHYLDOPA 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
321<\/td>DEFLAZACORT TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nDEFLAZACORT 1 MG
\nEXCIPIENTS Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
322<\/td>LOPERAMIDE CAPSULES IP 2 MG<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nLOPERAMIDE HYDROCHLORIDE IP 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULE SHELLS<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
323<\/td>LOPERAMIDE HYDROCHLORIDE TABLETS IP
\n<\/td>		EACH UNCOATED TABLET CONTAINS
\nLOPERAMIDE HYDROCHLORIDE IP 2 MG
\nEXCIPIENTS Q.S.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
324<\/td>CETIRIZINE TABLETS IP
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nCETIRIZINE DIHYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
325<\/td>CALCIUM CARBONATE & VITAMIN D3 TABLETS <\/td>EACH FILM-COATED TABLET CONTAINS
\nCALCIUM CARBONATE IP 1250 MG
\n(FROM AN ORGANIC SOURCE OYSTER SHELL)
\nEQUIVALENT TO
\nELEMENTAL CALCIUM 500 MG
\nVITAMIN D3 IP 500 IU
\n EXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
326<\/td>TADALAFIL TABLETS IP 10 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nTADALAFIL IP 10 MG EXCIPINTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Thursday, September 11, 2003<\/td><\/td>\n<\/tr>\n
327<\/td>TERBUTALINE SULPHATE, BROMHEXINE HYDROCHLORIDE,
\nGUAIPHENESIN TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nBROMHEXINE HYDROCHLORIDE IP 4 MG
\nTERBUTALINE SULPHATE IP 2.5 MG
\nGUAIPHENESIN IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
328<\/td>BROMOCRIPTINE MESYLATE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nBROMOCRIPTINE MESYLATE IP 2.87 MG
\nEQ. TO BROMOCRIPTINE 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1987-July <\/td><\/td>\n<\/tr>\n
329<\/td>TRANEXAMIC ACID TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nTRANEXAMIC ACID IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, March 06, 2002<\/td><\/td>\n<\/tr>\n
330<\/td>DRIED ALUMINIUM HYDROXIDE GEL, MAGNESIUM HYDROXIDE AND SIMETHICONE SUSPENSION<\/td>EACH 5 ML CONTAINS
\nDRIED ALUMINIUM HYDROXIDE GEL IP 200 MG
\nMAGNESIUM HYDROXIDE IP 200 MG
\nSIMETHICONE IP 25 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
331<\/td>SILDENAFIL CITRATE TABLETS IP 50 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nSILDENAFIL CITRATE IP
\nEQ.TO SILDENAFIL 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, January 08, 2001<\/td><\/td>\n<\/tr>\n
332<\/td>PARACETAMOL TABLETS IP 650 MG
\n<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 650 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/strong><\/td><\/td>\n<\/tr>\n
333<\/td>NIMESULIDE & PARACETAMOL TABLETS
\n<\/td>		EACH UNCOATED TABLET CONTAINS
\nNIMESULIDE BP 100 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nNOT FOR USE BELOW 12 YEARS OF AGE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
334<\/td>ACECLOFENAC & PARACETAMOL TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
335<\/td>CETIRIZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE AND PARACETAMOL TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nCETIRIZINE HYDROCHLORIDE IP 5 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
336<\/td>ACECLOFENAC & PARACETAMOL TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/strong><\/td><\/strong><\/td><\/td>\n<\/tr>\n
337<\/td>ACECLOFENAC, PARACETAMOL & CHLORZOXAZONE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nPARACETAMOL IP 325 MG
\nCHLORZOXAZONE USP 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/strong><\/td><\/strong><\/td><\/td>\n<\/tr>\n
338<\/td>DICLOFENAC POTASSIUM,
\nPARACETAMOL AND
\nCHLORZOXAZONE TABLETS
\n<\/td>		EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC POTASSIUM IP 50 MG
\nPARACETAMOL IP 325 MG
\nCHLORZOXAZONE USP 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/strong><\/td><\/strong><\/td><\/td>\n<\/tr>\n
339<\/td>GLIMEPIRIDE AND METFORMIN
\nHCl SUSTAINED RELEASE TABLETS
\n<\/td>
\nEACH UNCOATED BILAYERED TABLET CONTAINS
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HCl IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/strong><\/td>Sunday, November 13, 2022<\/td><\/td>\n<\/tr>\n
340<\/td>ONDANSETRON ORALLY DISINTEGRATING TABLETS IP<\/td>EACH UNCOATED ORALLY DISINTEGRATING TABLET CONTAINS
\nONDANSETRON HYDROCHLORIDE IP
\nEQ. TO ONDANSETRON 4 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Wednesday, October 10, 2007<\/td><\/td>\n<\/tr>\n
341<\/td>METFORMIN HYDROCHLORIDE TABLETS IP
\n<\/td>
\nEACH UNCOATED TABLET CONTAINS
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\n
\n<\/td>		IP<\/td>Friday, November 09, 2001<\/td><\/td>\n<\/tr>\n
342<\/td>METFORMIN HYDROCHLORIDE TABLETS IP
\n<\/td>
\nEACH FILM COATED TABLET CONTAINS
\nMETFORMIN HYDROCHLORIDE IP 850 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
343<\/td>GLIMEPIRIDE AND METFORMIN
\nHCl SUSTAINED RELEASE TABLETS
\n<\/td>
\nEACH UNCOATED BILAYERED TABLET CONTAINS
\nGLIMEPIRIDE IP 1 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Wednesday, November 13, 2002<\/td><\/td>\n<\/tr>\n
344<\/td>ONDANSETRON ORALLY DISINTEGRATING TABLETS <\/td>EACH UNCOATED ORALLY DISINTEGRATING TABLET CONTAINS
\nONDANSETRON HYDROCHLORIDE IP
\nEQ. TO ONDANSETRON 2 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
345<\/td>TENELIGLIPTIN AND METFORMIN
\nHYDROCHLORIDE PROLONGED RELEASE TABLETS IP
\n<\/td>
\nEACH UNCOATED BILAYER TABLET CONTAINS
\nTENELIGLIPTIN HYDROBROMIDE HYDRATE IP
\nEQ. TO TENELIGLIPTIN 20 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(PROLONGED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
346<\/td>DICLOFENAC SODIUM & PARACETAMOL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 50 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
347<\/td>TENELIGLIPTIN 20 MG AND METFORMIN
\nHYDROCHLORIDE (SR) 1000 MG TABLETS IP
\n<\/td>
\nEACH UNCOATED BILAYER TABLET CONTAINS
\nTENELIGLIPTIN HYDROBROMIDE HYDRATE IP
\nEQ. TO TENELIGLIPTIN 20 MG
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
348<\/td>TENELIGLIPTIN 20 MG AND METFORMIN
\nHYDROCHLORIDE (SR) 850 MG TABLETS
\n<\/td>
\nEACH UNCOATED BILAYER TABLET CONTAINS
\nTENELIGLIPTIN HYDROBROMIDE HYDRATE IP
\nEQ. TO TENELIGLIPTIN 20 MG
\nMETFORMIN HYDROCHLORIDE IP 850 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
349<\/td>CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN
\nHYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE & MENTHOL SYRUP<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 10 MG
\nPHENYLEPHRINE
\nHYDROCHLORIDE IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nMENTHOL IP 1.5 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
350<\/td>RABEPRAZOLE GASRTO-RESISTANT AND DOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL AND PELLETS<\/td>		<\/td>Monday, October 04, 2004<\/td><\/td>\n<\/tr>\n
351<\/td>ESOMEPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL AND PELLETS<\/td>		<\/td>Monday, June 26, 1905<\/td><\/td>\n<\/tr>\n
352<\/td>PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE &
\nCETIRIZINE DI-HYDROCHLORIDE TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 325 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nCETIRIZINE DI- HYDROCHLORIDE IP 5 MG
\nEXCPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
353<\/td>GLIMEPIRIDE, PIOGLITAZONE AND METFORMIN
\nHCl SUSTAINED RELEASE TABLETS
\n<\/td>
\nEACH UNCOATED BILAYER TABLET CONTAINS
\nGLIMEPIRIDE IP 2 MG
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 15 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Friday, August 12, 2005<\/td><\/td>\n<\/tr>\n
354<\/td>GLIMEPIRIDE, PIOGLITAZONE AND METFORMIN
\nHCl SUSTAINED RELEASE TABLETS
\n<\/td>
\nEACH UNCOATED BILAYER TABLET CONTAINS
\nGLIMEPIRIDE IP 1 MG
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 15 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Friday, August 12, 2005<\/td><\/td>\n<\/tr>\n
355<\/td>GLIMEPIRIDE TABLETS IP 1 MG
\n<\/td>
\nEACH UNCOATED TABLET CONTAINS
\nGLIMEPIRIDE IP 1 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Sunday, January 24, 1999<\/td><\/td>\n<\/tr>\n
356<\/td>PANTOPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE PROLONGED-RELEASE CAPSULES IP <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nPANTOPRAZOLE SODIUM SESQUIHYDRATE IP
\nEQ. TO PANTOPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS PROLONGED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS <\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
357<\/td>PARACETAMOL PAEDIATRIC ORAL SUSPENSION IP<\/td>EACH 5 ML CONTAINS
\nPARACETAMOL IP 125 MG
\nEXCIPIENTS Q.S
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
358<\/td>LEVOFLOXACIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVOFLOXACIN HEMIHYDRATE IP
\nEQ. TO LEVOFLOXACIN 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Friday, July 23, 1999<\/td><\/td>\n<\/tr>\n
359<\/td>ACECLOFENAC &
\nTHIOCOLCHICOSIDE TABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nACECLOFENAC IP 100 MG
\nTHIOCOLCHICOSIDE IP 4 MG
\nEXCIPIENTS Q.S
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
360<\/td>OFLOXACIN AND ORNIDAZOLE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nOFLOXACIN IP 200 MG
\nORNIDAZOLE IP 500 MG
\nEXCIPIENTS Q.S
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
361<\/td>PANTOPRAZOLE & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQ. TO PANTOPRAZOLE 40 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
362<\/td>DISODIUM HYDROGEN CITRATE SYRUP<\/td>EACH 5 ML CONTAINS:
\nDISODIUM HYDROGEN CITRATE BP 1.53 GM
\nFLAVOURED BASE Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
363<\/td>ENTECAVIR TABLETS IP 1 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nENTECAVIR IP 1 MG
\nEXCIPIENTS Q.S
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>Monday, December 05, 2005<\/td><\/td>\n<\/tr>\n
364<\/td>ENTECAVIR TABLETS IP 0.5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nENTECAVIR IP 0.5 MG
\nEXCIPIENTS Q.S
\n APPROVED COLOUR USED
\n<\/td>		<\/td>Monday, December 05, 2005<\/td><\/td>\n<\/tr>\n
365<\/td>OMEPRAZOLE GASTRO-RESISTANT CAPSULES IP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nOMEPRAZOLE IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL & PELLETS.
\n<\/td>		<\/td>Monday, April 01, 1991<\/td><\/td>\n<\/tr>\n
366<\/td>TERBINAFINE TABLETS IP 250 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nTERBINAFINE HYDROCHLORIDE IP
\nEQ. TO TERBINAFINE 250 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td>Wednesday, March 29, 1995<\/td><\/td>\n<\/tr>\n
367<\/td>TERBINAFINE TABLETS 500 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nTERBINAFINE HYDROCHLORIDE IP
\nEQ. TO TERBINAFINE 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
368<\/td>DROTAVERINE HYDROCHLORIDE & MEFENAMIC ACID TABLETS<\/td>EACH UNCOATED TABLET CONTAINS:
\nDROTAVERINE HYDROCHLORIDE IP 80 MG
\nMEFENAMIC ACID IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
369<\/td>FEXOFENADINE HYDROCHLORIDE TABLETS IP 120 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nFEXOFENADINE HYDROCHLORIDE IP 120 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Sunday, September 06, 1998<\/td><\/td>\n<\/tr>\n
370<\/td>POVIDONE-IODINE OINTMENT USP<\/td>CONTAINS:
\nPOVIDONE-IODINE IP 10% W\/W
\n(AVAILABLE IODINE 1.0% W\/W)
\nWATER-SOLUBLE OINTMENT BASE Q.S.
\n<\/td>		USP<\/td>Wednesday, November 01, 1972<\/td><\/td>\n<\/tr>\n
371<\/td>FEXOFENADINE HYDROCHLORIDE & MONTELUKAST TABLETS<\/td>EACH FILM-COATED TABLET CONTAINS
\nFEXOFENADINE HYDROCHLORIDE IP 120 MG
\nMONTELUKAST SODIUM IP
\nEQ. TO MONTELUKAST 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>Tuesday, August 31, 2010<\/td><\/td>\n<\/tr>\n
372<\/td>DICLOFENAC SODIUM & PARACETAMOL TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 50 MG
\nPARACETAMOL IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td>Wednesday, January 30, 2008<\/td><\/td>\n<\/tr>\n
373<\/td>ITRACONAZOLE CREAM 1% W\/W<\/td>COMPOSITION
\nITRACONAZOLE BP 1.00% W\/W
\nMETHYL PARABEN IP 0.10% W\/W
\nPROPYL PARABEN IP 0.025% W\/W
\nCREAM BASE Q.S.<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
374<\/td>POVIDONE-IODINE OINTMENT USP<\/td>CONTAINS:
\nPOVIDONE-IODINE IP 5 % W\/W
\n(AVAILABLE IODINE 1.0% W\/W)
\nWATER-SOLUBLE OINTMENT BASE Q.S.
\n<\/td>		USP<\/td>1972-November<\/td><\/td>\n<\/tr>\n
375<\/td>ETORICOXIB & PARACETAMOL TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 60 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
376<\/td>PARACETAMOL & MEFENAMIC ACID TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 325 MG
\nMEFENAMIC ACID IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
377<\/td>OMEPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE CAPSULES IP <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nOMEPRAZOLE IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL & PELLETS.<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
378<\/td>PANTOPRAZOLE & DOMPERIDONE TABLETS
\n<\/td>		EACH ENTERIC COATED TABLET CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQ. TO PANTOPRAZOLE 40 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED <\/td>		<\/td><\/td><\/td>\n<\/tr>\n
379<\/td>PARACETAMOL & IBUPROFEN SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nIBUPROFEN IP 100 MG
\nPARACETAMOL IP 162.50 MG
\nFLAVOURED SYRUP BASE Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
380<\/td>MONTELUKAST SODIUM &
\nLEVOCETIRIZINE HCL TABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nMONTELUKAST SODIUM IP
\nEQUIVALENT TO
\nMONTELUKAST 4 MG
\nLEVOCETIRIZINE HYDROCHLORIDE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
381<\/td>KETOCONAZOLE TABLETS IP 200 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nKETOCONAZOLE IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>1986-October <\/td><\/td>\n<\/tr>\n
382<\/td>DICYCLOMINE HYDROCHLORIDE & PARACETAMOL TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nDICYCLOMINE HYDROCHLORIDE IP 20 MG
\nPARACETAMOL IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		 <\/td><\/td><\/td>\n<\/tr>\n
383<\/td>PROCHLORPERAZINE MALEATE MOUTH DISSOLVING TABLET <\/td>EACH MOUTH DISSOLVING UNCOATED TABLET CONTAINS
\nPROCHLORPERAZINE MALEATE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
384<\/td>OXCARBAZEPINE TABLETS IP 300 MG<\/td>EACH FILM -COATED TABLET CONTAINS
\nOXCARBAZEPIN IP 300 MG
\nEXCIPENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>Monday, January 14, 2002<\/td><\/td>\n<\/tr>\n
385<\/td>GABAPENTIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nGABAPENTIN IP 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
386<\/td>GABAPENTIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nGABAPENTIN IP 300 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
387<\/td>PIRFENIDONE TABLETS IP 200 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nPIRFENIDONE IP 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>9\/14\/2010<\/td><\/td>\n<\/tr>\n
388<\/td>TICAGRELOR TABLETS IP 90 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nTICAGRELOR IP 90 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>5\/3\/2012<\/td><\/td>\n<\/tr>\n
389<\/td>DAPAGLIFLOZIN TABLETS 10 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nDAPAGLIFLOZIN 200 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
390<\/td>TORSEMIDE TABLETS IP 20 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nTORSEMIDE IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
391<\/td>SITAGLIPTIN PHOSPHATE
\nTABLETS IP <\/td>		EACH FILM COATED TABLET CONTAINS:
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP
\nEQ. TO SITAGLIPTIN 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		<\/td>7\/3\/2010<\/td><\/td>\n<\/tr>\n
392<\/td>SITAGLIPTIN PHOSPHATE
\nTABLETS IP <\/td>		EACH FILM COATED TABLET CONTAINS:
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP
\nEQ. TO SITAGLIPTIN 100 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED<\/td>		IP<\/td>7\/3\/2010<\/td><\/td>\n<\/tr>\n
393<\/td>GLICLAZIDE EXTENDED RELEASE TABLETS 60 MG <\/td>EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nGLICLAZIDE IP 60 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>8\/14\/2007<\/td><\/td>\n<\/tr>\n
394<\/td>GLICLAZIDE EXTENDED RELEASE TABLETS 120 MG <\/td>EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nGLICLAZIDE IP 120 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
395<\/td>GLICLAZIDE TABLETS IP 80 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nGLICLAZIDE IP 80 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td>Nov. 1988<\/td><\/td>\n<\/tr>\n
396<\/td>METOPROLOL SUCCINATE PROLONGED-RELEASE
\nAND AMLODIPINE TABLETS IP<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\n(AS PROLONGED-RELEASE)
\nAMLODIPINE BESILATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>07 Feb.
\n2006
\n<\/td>		<\/td>\n<\/tr>\n
397<\/td>TELMISARTAN AND METOPROLOL SUCCINATE
\nPROLONGED-RELEASE TABLETS <\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\n(AS PROLONGED-RELEASE)
\nEXCIPIENTS Q.S.
\n COLOUR: QUINOLINE YELLOW
\n<\/td>		<\/td>16 Jul.
\n2010
\n<\/td>		<\/td>\n<\/tr>\n
398<\/td>METOPROLOL SUCCINATE PROLONGED-RELEASE
\n AND AMLODIPINE TABLETS IP<\/td>		EACH FILM COATED BILAYERED TABLET CONTAINS
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\n(AS PROLONGED-RELEASE)
\nAMLODIPINE BESILATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>07 Feb.
\n2006
\n<\/td>		<\/td>\n<\/tr>\n
399<\/td>ROSUVASTATIN, ASPIRIN
\nAND CLOPIDOGREL CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 10 MG
\nCLOPIDOGREL BISULPHATE IP
\nEQ. TO CLOPIDOGREL 75 MG
\nASPIRIN IP 75 MG
\n(AS ENTERIC COATED)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
400<\/td>ROSUVASTATIN, ASPIRIN
\n AND CLOPIDOGREL CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 20 MG
\nCLOPIDOGREL BISULPHATE IP
\nEQ. TO CLOPIDOGREL 75 MG
\nASPIRIN IP 75 MG
\n(AS ENTERIC COATED)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
401<\/td>FLUOXETINE HYDROCHLORIDE
\n TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQ. TO FLUOXETINE 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: PONCEAU 4 R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
402<\/td>ZONISAMIDE TABLETS 100 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nZONISAMIDE IP 100 MG
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
403<\/td>CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN
\nHYDROBROMIDE, PHENYLEPHRINE HYDROCHLORIDE & MENTHOL SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HBr IP 10 MG
\nPHENYLEPHRINE
\nHYDROCHLORIDE IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nMENTHOL IP 1.5 MG
\nFLAVOURED SYRUPY BASE Q.S.
\n COLOUR: PONCEAU 4 R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
405<\/td>GABAPENTIN & NORTRIPTYLINE HCL TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nGABAPENTIN IP 400 MG
\nNORTRIPTYLINE HYDROCHLORIDE IP
\nEQ. TO NORTRIPTYLINE 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
406<\/td>TAMSULOSIN HYDROCHLORIDE (MODIFIED RELEASE) DUTASTERIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nTAMSULOSIN HYDROCHLORIDE IP 0.4 MG
\n(AS MODIFIED RELEASE)
\nDUTASTERIDE IP 0.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n
\n<\/td>		<\/td>06 Feb.
\n2006
\n<\/td>		<\/td>\n<\/tr>\n
407<\/td>CHLORAMPHENICOL, BENZOCAINE AND
\n PROPYLENE GLYCOL EAR DROPS
\n<\/td>		COMPOSITION
\nEACH ML CONTAINS
\nCHLORAMPHENICOL IP 5% W\/V
\nBENZOCAINE IP 1% W\/V
\nPROPYLENE GLYCOL IP Q.S.
\n(AS BASE)
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
408<\/td>SUCRALFATE &
\nOXETACAINE SUSPENSION
\n<\/td>		EACH 10 ML CONTAINS
\nSUCRALFATE IP 1 G
\nOXETACAINE BP 20 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
409<\/td>DUTASTERIDE TABLETS 0.5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nDUTASTERIDE IP 0.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
410<\/td>DROTAVERINE HYDROCHLORIDE &
\nMEFENAMIC ACID TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nDROTAVERINE HYDROCHLORIDE IP 80 MG
\nMEFENAMIC ACID IP 250 MG
\nEXCIPIENTS Q.S.
\n COLOUR: ERYTHROSINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
411<\/td>POVIDONE IODINE OINTMENT USP<\/td>COMPOSITION
\nPOVIDONE IODINE IP 5% W\/W
\n(0.5%W\/W AVAILABLE IODINE)
\nOINTMENT BASE Q.S.
\n<\/td>		USP<\/td>Sep. 1978<\/td><\/td>\n<\/tr>\n
412<\/td>DRIED ALUMINIUM HYDROXIDE,
\nMAGNESIUM HYDROXIDE &
\nOXETACAINE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nDRIED ALUMINIUM HYDROXIDE IP 0.291 G
\nMAGNESIUM HYDROXIDE IP 98 MG
\nOXETACAINE BP 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: ERYTHROSINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
413<\/td>HYDROXYZINE
\nHYDROCHLORIDE SYRUP <\/td>		EACH 5 ML CONTAINS
\nHYDROXYZINE HYDROCHLORIDE IP 10 MG
\nFLAVOURED SYRUPY BASE
\n COLOUR: YELLOW OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
414<\/td>RIFAXIMIN TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nRIFAXIMIN BP 400 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>18 Jul.
\n2009
\n<\/td>		<\/td>\n<\/tr>\n
415<\/td>LEVETIRACETAM TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVETIRACETAM IP 750 MG
\nEXCIPIENTS Q.S.
\n COLOUR: FERRIC OXIDE OF YELLOW & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>5-Apr-05<\/td><\/td>\n<\/tr>\n
416<\/td>BILASTINE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nBILASTINE 20 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
417<\/td>DICLOFENAC POTASSIUM & PARACETAMOL TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC POTASSIUM IP 50 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
418<\/td>AMBROXOL HCL, TERBUTALINE, GUAIPHENESIN AND
\nMENTHOL SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 15 MG
\nTERBUTALINE SULPHATE IP 1.25 MG
\nGUAIPHENESIN IP 50 MG
\nMENTHOL IP 2.5 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		<\/td>26-Mar-08<\/td><\/td>\n<\/tr>\n
419<\/td>CETIRIZINE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCETIRIZINE DIHYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td>12 Dec.
\n2002
\n<\/td>		<\/td>\n<\/tr>\n
420<\/td>LEVOCETIRIZINE
\nDIHYDROCHLORIDE TABLETS IP<\/td>		EACH FILM COATED TABLET CONTAINS
\nLEVOCETIRIZINE DIHYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
421<\/td>CALCIUM CARBONATE &
\n VITAMIN D3 TABLETS <\/td>		EACH FILM-COATED TABLET CONTAINS
\nCALCIUM CARBONATE IP 1250 MG
\n(FROM AN ORGANIC SOURCE OYSTER SHELL)
\nEQUIVALENT TO
\nELEMENTAL CALCIUM 500 MG
\nVITAMIN D3 IP 500 IU
\n EXCIPIENTS Q.S.
\n COLOUR: BRILLIANT BLUE & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
422<\/td>METFORMIN HYDROCHLORIDE
\nPROLONGED RELEASE TABLETS IP 500 MG<\/td>		EACH UNCOATED PROLONGED RELEASE TABLETS CONTAINES
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>09 Nov.
\n2001
\n<\/td>		<\/td>\n<\/tr>\n
423<\/td>METFORMIN HYDROCHLORIDE PROLONGED
\n RELEASE TABLETS IP 1000 MG<\/td>		EACH UNCOATED PROLONGED RELEASE TABLETS CONTAINES
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>2002<\/td><\/td>\n<\/tr>\n
424<\/td>PARACETAMOL, CHLORPHENAMINE MALEATE
\n AND PHENYLEPHRINE HCL TABLETS<\/td>		EACH UNCOATED TABLETS CONTAINES:
\nPARACETAMOL IP 325 MG
\nCHLORPHENAMINE MALEATE IP 2 MG
\nPHENYLEPHRINE HCL IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
425<\/td>CITICOLINE TABLETS IP<\/td>EACH FILM COATED TABLETS CONTAINES
\nCITICOLINE SODIUM IP
\nEQUIVALENT TO CITICOLINE 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>31 Oct.
\n2008
\n<\/td>		<\/td>\n<\/tr>\n
426<\/td>ORLISTAT CAPSULES USP
\n120 MG <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nORLISTAT USP 120 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS
\n<\/td>		USP<\/td>22 Aug.
\n2007
\n<\/td>		<\/td>\n<\/tr>\n
427<\/td>PARACETAMOL, PHENYLEPHRINE HCl, CAFFEINE
\n AND DIPHENHYDRAMINE HCl TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 325 MG
\nPHENYLEPHRINE Hcl IP 5 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE Hcl IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
428<\/td>FLUPENTIXOL AND MELITRACEN TABLETS<\/td>EACH FILM COATED TABLETS CONTAINES
\nFLUPENTIXOL HYDROCHLORIDE BP
\nEQUIVALENT TO FLUPENTIXOL 0.5 MG
\nMELITRACEN HYDROCHLORIDE
\nEQUIVALENT TO MELITRACEN 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: ERYTHROSINE
\n<\/td>		<\/td>28 Oct.
\n1998
\n<\/td>		<\/td>\n<\/tr>\n
429<\/td>TELMISARTAN 40 MG AND
\nCHLORTHALIDONE 6.25 MG TABLETS<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINES
\nTELMISARTAN IP 40 MG
\nCHLORTHALIDONE IP 6.25 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
430<\/td>LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nLEVOCETIRIZINE DIHYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td>14 Jan.
\n2015
\n<\/td>		<\/td>\n<\/tr>\n
431<\/td>PHENYLEPHRINE HCL, CHLORPHENIRAMINE
\nMALEATE AND SODIUM CITRATE SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nPHENYLEPHRINE HCl IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nSODIUM CITRATE IP 60 MG
\nIN A FLAVOURED SYRUPY BASE Q.S.
\nCOLOUR: PONCEAU-4R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
432<\/td>DIVALPROEX SODIUM EXTENDED RELEASE
\n TABLETS IP 750 MG<\/td>		EACH FILM-COATED EXTENDED RELEASE TABLET CONTAINS
\nDIVALPROEX SODIUM IP
\nEQ. TO VALPROIC ACID 750 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE BLACK & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>25-Jun-04<\/td><\/td>\n<\/tr>\n
433<\/td>ROXITHROMYCIN TABLETS IP 150 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nROXITHROMYCIN IP 150 MG
\nEXCIPIENTS Q.S.
\n COLOUR: LAKE OF BRILLIANT BLUE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>27 Mar. 1992<\/td><\/td>\n<\/tr>\n
434<\/td>LETROZOLE TABLETS IP 2.5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nLETROZOLE IP 2.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: YELLOW OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>11 Feb. 2002<\/td><\/td>\n<\/tr>\n
435<\/td>RUPATADINE TABLETS 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nRUPATADINE FUMARATE IP
\nEQ. TO RUPATADINE 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>05 Apr. 2005<\/td><\/td>\n<\/tr>\n
436<\/td>ATENOLOL TABLETS IP 50 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nATENOLOL IP 50 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>Sep. 1985<\/td><\/td>\n<\/tr>\n
437<\/td>ETORICOXIB TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 90 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: PEA GREEN & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
438<\/td>SODIUM PICOSULPHATE TABLETS 10 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nSODIUM PICOSULPHATE BP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		<\/td>11 Feb. 1997<\/td><\/td>\n<\/tr>\n
439<\/td>MOXIFLOXACIN HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nMOXIFLOXACIN HCl IP
\nEQ. TO MOXIFLOXACIN 400 MG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>6-Jun-01<\/td><\/td>\n<\/tr>\n
440<\/td>PARACETAMOL, PHENYLEPHRINE HCl, CAFFEINE
\n AND DIPHENHYDRAMINE HCl TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE Hcl IP 5 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE Hcl IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>13 Oct. 2010<\/td><\/td>\n<\/tr>\n
441<\/td>ESOMEPRAZOLE GASTRO-RESISTANT AND
\n DOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 20 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 10 MG
\n(AS IMMEDIATE-RELEASE PELLETS)
\nDOMPERIDONE IP 20 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL AND PELLETS
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
442<\/td>METFORMIN HYDROCHLORIDE
\nPROLONGED-RELEASE AND GLIMEPIRIDE TABLETS IP<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nMETFORMIN HCL IP 1000 MG
\n(IN PROLONGED-RELEASE FROM)
\nGLIMEPIRIDE IP 2 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TARTRAZINE
\n<\/td>		IP<\/td>8-Jun-07<\/td><\/td>\n<\/tr>\n
443<\/td>METFORMIN HYDROCHLORIDE PROLONGED-RELEASE AND GLIMEPIRIDE TABLETS IP <\/td>EACH UNCOATED BILAYERED TABLET CONTAINS
\nMETFORMIN HCL IP 1000 MG
\n(IN PROLONGED-RELEASE FROM)
\nGLIMEPIRIDE IP 1 MG
\nEXCIPIENTS Q.S.
\n COLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td>8-Jun-07<\/td><\/td>\n<\/tr>\n
444<\/td>TELMISARTAN TABLETS IP 40 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>25 Nov. 2002<\/td><\/td>\n<\/tr>\n
445<\/td>TELMISARTAN AND HYDROCHLORTHIAZIDE
\nTABLETS IP<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\n HYDROCHLORTHIAZIDE IP 12.5 MG
\n EXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		IP<\/td>29 Aug. 2003<\/td><\/td>\n<\/tr>\n
446<\/td>VILDAGLIPTIN AND METFORMIN
\nHYDROCHLORIDE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nVILDAGLIPTIN 50 MG
\nMETFORMIN HCL IP 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON & TITANIUM DIOXIDE IP
\n
\n<\/td>		<\/td>21 Jul. 2008<\/td><\/td>\n<\/tr>\n
447<\/td>VILDAGLIPTIN TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nVILDAGLIPTIN 50 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>25 Jul. 2008<\/td><\/td>\n<\/tr>\n
448<\/td>ESOMEPRAZOLE 40 MG (EC) & ITOPRIDE
\nHYDROCHLORIDE 150 MG (SR) CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nITOPRIDE HCl IP 150 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL & PELLETS.
\n<\/td>		<\/td>13-Nov-06<\/td><\/td>\n<\/tr>\n
449<\/td>PANTOPRAZOLE 40 MG (EC) & ITOPRIDE
\n HYDROCHLORIDE 150 MG (SR) CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nPANTOPRAZOLE SODIUM SESQUIHYDRATE IP
\nEQ. TO PANTOPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nITOPRIDE HCl IP 150 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL & PELLETS.
\n<\/td>		<\/td>8-Apr-06<\/td><\/td>\n<\/tr>\n
450<\/td>ESOMEPRAZOLE GASTRO-RESISTANT AND
\nDOMPERIDONE SUSTAINED-RELEASE CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 10 MG
\n(AS IMMEDIATE-RELEASE PELLETS)
\nDOMPERIDONE IP 20 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL AND PELLETS
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
451<\/td>ITOPRIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nITOPRIDE HYDROCHLORIDE IP 50 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>9-May-02<\/td><\/td>\n<\/tr>\n
452<\/td>ITOPRIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nITOPRIDE HYDROCHLORIDE IP 150 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
453<\/td>RANITIDINE ORAL SOLUTION IP<\/td>EACH 5 ML CONTAINS
\nRANITIDINE HYDROCHLORIDE IP
\nEQ. TO RANITIDINE 75 MG
\nFLAVOURED SYRUP BASE
\nCOLOUR: QUINOLINE YELLOW WS
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
454<\/td>CITICOLINE AND PIRACETAM
\n TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nCITICOLINE SODIUM IP
\nEQ. TO CITICOLINE 500 MG
\nPIRACETAM IP 800 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
455<\/td>PREGABALIN SUSTAINED RELEASE &
\nMETHYLCOBALAMIN TABLETS <\/td>		EACH UNCOATED TABLETS CONTAINS
\nPREGABALIN IP 75 MG
\n(IN SUSTAINED RELEASE FORM)
\nMETHYLCOBALAMIN IP 1500 MCG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td>9-Feb-10<\/td><\/td>\n<\/tr>\n
456<\/td>CHLORPHENIRAMINE MALEATE &
\n PHENYLEPHRINE HYDROCHLORIDE SYRUP <\/td>		EACH 5 ML CONTAINS
\nCHLORPHENIRAMINE
\nMALEATE IP 2 MG
\nPHENYLEPHRINE HCl IP 5 MG
\nIN A FLAVOURED SYRUP BASE
\nCOLOUR:PANCEAU 4R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
457<\/td>FERACRYLUM GEL 1 % W\/W<\/td>COMPOSITION
\nFERACRYLUM 1 % W\/W
\nWATER MISCIBLE BASE Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
458<\/td>TAMSULOSIN HYDROCHLORIDE MODIFIED RELEASE AND DEFLAZACORT CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nTAMSULOSIN HYDROCHLORIDE IP 0.4 MG
\n(AS FILM COATED MODIFIED RELEASE TABLETS)
\nCOLOUR: TITANIUM DIOXIDE IP
\nDEFLAZACORT 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
459<\/td>DICYCLOMINE HYDROCHLORIDE & PARACETAMOL CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nDICYCLOMINE HCl IP 20 MG
\nPARACETAMOL IP 325 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
460<\/td>CETIRIZINE HYDROCHLORIDE
\n TABLETS IP<\/td>		EACH FILM COATED TABLET CONTAINS
\nCETIRIZINE HYDROCHLORIDE IP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
461<\/td>PARACETAMOL, PHENYLEPHRINE
\nHCl, CAFFEINE AND DIPHENHYDRAMINE
\nHCl TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE Hcl IP 5 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE Hcl IP 25 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		<\/td>10\/13\/2010<\/td><\/td>\n<\/tr>\n
462<\/td>TRIHEXYPHENIDYL HYDROCHLORIDE
\nTABLETS IP 2 MG<\/td>		EACH UNCOATED TABLET CONTAINS
\nTRIHEXYPHENIDYL HYDROCHLORIDE IP 2 MG EXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
463<\/td>BENZHEXOL HYDROCHLORIDE
\n TABLETS IP<\/td>		EACH UNCOATED TABLET CONTAINS
\nBENZHEXOL HYDROCHLORIDE IP 5 MG
\n EXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
464<\/td>PARACETAMOL AND
\nTHIOCOLCHICOSIDE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nPARACETAMOL IP 325 MG
\nTHIOCOLCHICOSIDE IP 4 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
465<\/td>ATORVASTATIN TABLETS
\n IP 80 MG<\/td>		EACH FILM COATED TABLET CONTAIN
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 80 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>2\/25\/2008<\/td><\/td>\n<\/tr>\n
466<\/td>DEXLANSOPRAZOLE
\nMODIFIED RELEASE AND
\nDOMPERIDONE SUSTAINED
\nRELEASE CAPSULES<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nDEXLANSOPRAZOLE IP 30 MG
\n(AS MODIFIED RELEASE PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
467<\/td>DEXLANSOPRAZOLE MODIFIED
\n RELEASE AND DOMPERIDONE
\n SUSTAINED RELEASE CAPSULES<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nDEXLANSOPRAZOLE IP 60 MG
\n(AS MODIFIED RELEASE PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
468<\/td>DEXLANSOPRAZOLE MODIFIED
\n RELEASE CAPSULES<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nDEXLANSOPRAZOLE IP 60 MG
\n(AS MODIFIED RELEASE PELLETS)
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS.
\n<\/td>		<\/td>1\/16\/2017<\/td><\/td>\n<\/tr>\n
469<\/td>MONTELUKAST SODIUM AND
\nDESLORATADINE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nMONTELUKAST SODIUM IP
\nEQ. TO MONTELUKAST 10 MG
\nDESLORATADINE BP 5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
470<\/td>DEXLANSOPRAZOLE MODIFIED
\nRELEASE CAPSULES<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nDEXLANSOPRAZOLE IP 30 MG
\n(AS MODIFIED RELEASE PELLETS)
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS.
\n<\/td>		<\/td>1\/16\/2017<\/td><\/td>\n<\/tr>\n
471<\/td>VILDAGLIPTIN AND METFORMIN
\nHYDROCHLORIDE (SR) TABLETS <\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nVILDAGLIPTIN 50 MG
\nMETFORMIN HCL IP 500 MG
\n(AS SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: QUINOLINE YELLOW
\n<\/td>		<\/td>21 JUL. 2008<\/td><\/td>\n<\/tr>\n
472<\/td>TELMISARTAN &
\nCHLORTHALIDONE TABLETS <\/td>		EACH UNCOATED BILAYER TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nCHLORTHALIDONE IP 6.25 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE RED & FERRIC OXIDE YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
473<\/td>METOPROLOL SUCCINATE EXTENDED
\nRELEASE TABLETS IP<\/td>		EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\nMETOPROLOL SUCCINATE IP 23.75 MG
\nEQ. TO METOPROLOL TARTRATE 25 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>11\/29\/2004<\/td><\/td>\n<\/tr>\n
474<\/td>METOPROLOL SUCCINATE
\nEXTENDED RELEASE TABLETS IP<\/td>		EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>11\/29\/2004<\/td><\/td>\n<\/tr>\n
475<\/td>L-ORNITHINE L-ASPARTATE
\nTABLETS 500 MG<\/td>		EACH FILM COATED TABLET CONTAINS
\n L-ORNITHINE
\nL-ASPARTATE 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
476<\/td>L-ORNITHINE-
\nL-ASPARTATE SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\n L-ORNITHINE-
\n L-ASPARTATE 250 MG
\n IN FLAVOURE SYRUPY BASE Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
477<\/td>LIQUID PARAFFIN & MILK OF
\n MAGNESIA ORAL EMULSION<\/td>		EACH 15 ML CONTAINS:
\nLIQUID PARAFFIN IP 3.75 ML
\nMILK OF MAGNESIA IP 11.25 ML
\nIN A FLAVOURED SYRUP BASE Q.S.
\nCOLOUR: CARMOSINE & PONCEAU 4R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
478<\/td>RUPATADINE TABLETS 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nRUPATADINE FUMARATE IP
\nEQ. TO RUPATADINE 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>05 APR. 2005<\/td><\/td>\n<\/tr>\n
479<\/td>ATENOLOL TABLETS IP 50 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nATENOLOL IP 50 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>SEP. 1985<\/td><\/td>\n<\/tr>\n
480<\/td>ETORICOXIB TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nETORICOXIB IP 90 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: PEA GREEN & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
481<\/td>SODIUM PICOSULPHATE TABLETS 10 MG <\/td>EACH FILM COATED TABLET CONTAINS
\nSODIUM PICOSULPHATE BP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		<\/td>11 FEB. 1997<\/td><\/td>\n<\/tr>\n
482<\/td>MOXIFLOXACIN HYDROCHLORIDE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nMOXIFLOXACIN HCL IP
\nEQ. TO MOXIFLOXACIN 400 MG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		06IP<\/td>6-Jun-01<\/td><\/td>\n<\/tr>\n
483<\/td>PARACETAMOL, PHENYLEPHRINE HCL,
\nCAFFEINE AND DIPHENHYDRAMINE HCL
\nTABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE HCL IP 5 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE HCL IP 25 MG
\nEXCIPIENTS
\n<\/td>		<\/td>13 OCT. 2010<\/td><\/td>\n<\/tr>\n
484<\/td>PREGABALIN 75 MG (PROLONGED RELEASE)
\nAND ETORICOXIB TABLETS <\/td>		EACH FILM COATED BILAYERED TABLET CONTAINS
\nPREGABALIN IP 75 MG
\n(AS PROLONGED RELEASE)
\nETORICOXIB IP 60 MG
\nEXCIPIENTS Q.S.
\n COLOUR: ERYTHROSINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
485<\/td>TAMSULOSIN HYDROCHLORIDE
\n (MODIFIED RELEASE) DUTASTERIDE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nTAMSULOSIN HYDROCHLORIDE IP 0.4 MG
\n(AS MODIFIED RELEASE)
\nDUTASTERIDE IP 0.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td>06 FEB.
\n2006
\n<\/td>		<\/td>\n<\/tr>\n
486<\/td>DEXTROMETHORPHAN HYDROBROMIDE,
\nCHLORPHENIRAMINE MALEATE AND
\nPHENYLEPHRINE HYDROCHLORIDE
\nFLAVOURED DISPERSIBLE
\nTABLETS
\n<\/td>		EACH UNCOATED FLAVOURED DISPERSIBLE TABLET CONTAINS
\nDEXTROMETHORPHAN HBR IP 10 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nPHENYLEPHRINE HCL IP 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
487<\/td>BILASTINE & MONTELUKAST TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nBILASTINE 20 MG
\nMONTELUKAST SODIUM IP
\nEQ. TO MONTELUKAST 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
488<\/td>OMEPRAZOLE MAGNESIUM TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nOMEPRAZOLE MAGNESIUM IP
\nEQ. TO OMEPRAZOLE 40 MG
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
489<\/td>METHYLPREDNISOLONE
\nTABLETS IP<\/td>		EACH UNCOATED TABLET CONTAINS:
\nMETHYLPREDNISOLONE IP 16 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
490<\/td>METHYLPREDNISOLONE
\nTABLETS IP<\/td>		EACH UNCOATED TABLET CONTAINS:
\nMETHYLPREDNISOLONE IP 8 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>9\/1\/2009<\/td><\/td>\n<\/tr>\n
491<\/td>CARISOPRODOL TABLETS IP
\n350 MG <\/td>		EACH UNCOATED TABLET CONTAINS:
\nCARISOPRODOL IP 350 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
492<\/td>MIRTAZAPINE TABLETS IP 15 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\n MIRTAZAPINE IP 15 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		IP<\/td>2\/13\/2001<\/td><\/td>\n<\/tr>\n
493<\/td>RIFAXIMIN TABLETS <\/td>EACH FILM COATED TABLET CONTAINS:
\nRIFAXIMIN BP 550 MG
\n EXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW FCF & TITANIUM DIOXIDE IP
\n<\/td>		<\/td>8\/18\/2011<\/td><\/td>\n<\/tr>\n
494<\/td>DEFLAZACORT SUSPENSION <\/td>EACH 5 ML CONTAINS:
\nDEFLAZACORT 6 MG
\nIN A FLAVOURED SYRUPY BASE Q.S.
\nCOLOUR: QUINOLINE YELLOW
\n<\/td>		<\/td>6\/15\/2007<\/td><\/td>\n<\/tr>\n
495<\/td>CHLORHEXIDINE GLUCONATE 0.2% AND
\nMENTHOL 0.1% MOUTH WASH <\/td>		COMPOSITION
\nCHLORHEXIDINE GLUCONATE SOLUTION IP
\nEQ. TO CHLORHEXIDINE GLUCONATE 0.20 % W\/W
\nMENTHOL 0.10 % W\/W
\nAQUEOUS BASE Q.S.
\nCOLOUR: BRILLIANT BLUE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
496<\/td>GLICLAZIDE (MR) AND METFORMIN
\nHYDROCHLORIDE (SR) TABLETS<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLICLAZIDE IP 30 MG
\n(AS MODIFIED RELEASED)
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(AS SUSTAINED RELEASE FORM)
\nCOLOUR: QUINILINE YELLOW
\n<\/td>		<\/td>4\/27\/2005<\/td><\/td>\n<\/tr>\n
497<\/td>GLICLAZIDE (MR) AND METFORMIN
\n HYDROCHLORIDE (SR) TABLETS<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLICLAZIDE IP 60 MG
\n(AS MODIFIED RELEASED)
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(AS SUSTAINED RELEASE FORM)
\nCOLOUR: ERYTHROSINE
\n<\/td>		<\/td>4\/27\/2005<\/td><\/td>\n<\/tr>\n
498<\/td>GLICLAZIDE (SR), METFORMIN HYDROCHLORIDE
\n (SR) & PIOGLITAZON TABLETS<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLICLAZIDE IP 60 MG
\n(AS SUSTAINED RELEASE FORM)
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(AS SUSTAINED RELEASE FORM)
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZON 15 MG
\nCOLOUR: QUINILINE YELLOW
\n<\/td>		<\/td>5\/28\/2010<\/td><\/td>\n<\/tr>\n
499<\/td>GLICLAZIDE (SR), METFORMIN HYDROCHLORIDE
\n (SR) & PIOGLITAZON TABLETS<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLICLAZIDE IP 60 MG
\n(AS SUSTAINED RELEASE FORM)
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(AS SUSTAINED RELEASE FORM)
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZON 15 MG
\nCOLOUR: SUNSET YELLOW
\n<\/td>		<\/td>5\/28\/2010<\/td><\/td>\n<\/tr>\n
500<\/td>DICLOFENAC TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 50 MG
\nEXCIEPINTS Q.S.
\n<\/td>		IP<\/td>SEP.
\n1985
\n<\/td>		<\/td>\n<\/tr>\n
501<\/td>PARACETAMOL, PHENYLEPHRINE HCL &
\nCHLORPHENIRAMINE MALEATE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nPARACETAMOL IP 125 MG
\nPHENYLEPHRINE HCL IP 5 MG
\nCHLORPHENIRAMINE MALEATE IP 1 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nCOLOUR: SUNSET YELLOW FCF
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
502<\/td>CALCIUM CARBONATE, VITAMIN D3,
\nMETHYLCOBALAMIN, L-METHYLFOLATE
\nCALCIUM & PYRIDOXAL-5-PHOSPHATE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nCALCIUM CARBONATE IP 1250 MG
\nVITAMIN D3 IP 2000 IU
\nMETHYLCOBALAMIN IP 1500 MCG
\nCALCIUM
\nL-5-METHYLTETRAHYDROFOLATE USP 1 MG
\n(L-METHYLFOLATE CALCIUM)
\nPYRIDOXAL-5-PHOSPHATE 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
503<\/td>FRUSEMIDE TABLETS IP 40 MG<\/td>EACH UNCOATED TABLETS CONTAINS
\nFRUSEMIDE IP 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
504<\/td>PARACETAMOL, PHENYLEPHRINE HCL, CAFFEINE
\n AND DIPHENHYDRAMINE HCL TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE HCL IP 10 MG
\nCAFFEINE (ANHYDROUS) IP 25 MG
\nDIPHENHYDRAMINE HCL IP 25 MG
\nEXCIPIENTS
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
505<\/td>LOXAPINE CAPSULES USP<\/td>EACH HARD GELATIN CAPSULE CONTAINS:
\nLOXAPINE SUCCINATE USP
\nEQ. TO LOXAPINE 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULES SHELL AND PELLETS
\n<\/td>		USP<\/td>SEP.
\n1990
\n<\/td>		<\/td>\n<\/tr>\n
506<\/td>GLIPIZIDE TABLETS IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nGLIPIZIDE IP 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>21.08.
\n1996
\n<\/td>		<\/td>\n<\/tr>\n
507<\/td>CINNARIZINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nCINNARIZINE IP 25 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td>AUG.
\n1985
\n<\/td>		<\/td>\n<\/tr>\n
508<\/td>CHLORAMPHENICOL CAPSULES IP<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nCHLORAMPHENICOL IP 500 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS
\n<\/td>		IP<\/td>OCT.
\n1972
\n<\/td>		<\/td>\n<\/tr>\n
509<\/td>ESCITALOPRAM OXALATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nESCITALOPRAM OXALATE IP
\nEQ. TO ESCITALOPRAM 20 MG
\nEXCIPIENTS Q.S.
\n COLOUR: YELLOW OXIDE OF IRON
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
510<\/td>METOPROLOL SUCCINATE & RAMIPRIL TABLETS<\/td>EACH FILM COATED TABLET CONTAINS
\nMETOPROLOL SUCCINATE IP 23.75 MG
\nEQ. TO METOPROLOL TARTRATE 25 MG
\nRAMIPRIL IP 2.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: SUNSET YELLOW
\n<\/td>		<\/td>26.02.07<\/td><\/td>\n<\/tr>\n
511<\/td>CARVEDILOL EXTENDED RELEASE TABLETS 10 MG<\/td>EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nCARVEDILOL IP 10 MG
\nEXCIPIENTS Q.S
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
512<\/td>CARVEDILOL EXTENDED RELEASE TABLETS 20 MG<\/td>EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nCARVEDILOL IP 20 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
513<\/td>ITOPRIDE HYDROCHLORIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nITOPRIDE HYDROCHLORIDE IP 50 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td>09.05.02<\/td><\/td>\n<\/tr>\n
514<\/td>CARVEDILOL EXTENDED
\nRELEASE TABLETS 25 MG<\/td>		EACH UNCOATED EXTENDED RELEASE TABLET CONTAINS
\nCARVEDILOL IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
515<\/td>NORTRIPTYLINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nNORTRIPTYLINE HYDROCHLORIDE IP
\nEQ.TO NORTRIPTYLINE 25 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
516<\/td>PIROXICAM DISPERSIBLE TABLETS 20 MG<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS
\nPIROXICAM IP 20 MG
\n(IN A FLAVORED BASE)
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
517<\/td>RANITIDINE TABLETS IP 150 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nRANITIDINE HYDROCHLORIDE IP
\nEQ. TO RANITIDINE 150 MG
\nEXCIPIENTS Q.S.
\n COLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
518<\/td>PREDNISOLONE TABLETS IP 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nPREDNISOLONE IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>DEC.
\n1971
\n<\/td>		<\/td>\n<\/tr>\n
519<\/td>CINNARIZINE & DOMPERIDONE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCINNARIZINE IP 20 MG
\nDOMPERIDONE IP 15 MG
\nEXCIPIENTS Q.S.
\n COLOUR: TARTRAZINE YELLOW
\n<\/td>		<\/td>FEB.
\n1992
\n<\/td>		<\/td>\n<\/tr>\n
520<\/td>DIACEREIN CAPSULES IP 50 MG<\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nDIACEREIN IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS
\n<\/td>		IP<\/td>2004<\/td><\/td>\n<\/tr>\n
521<\/td>GLIBENCLAMIDE TABLETS IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nGLIBENCLAMIDE IP 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
522<\/td>HALOPERIDOL TABLETS IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nHALOPERIDOL IP 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
523<\/td>AMBROXOL HYDROCHLORIDE &
\nLEVOCETIRIZINE HYDROCHLORIDE TABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nAMBROXOL HYDROCHLORIDE IP 60 MG
\nLEVOCETIRIZINE HYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: QUINOLINE YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
524<\/td>SALBUTAMOL TABLETS IP 2 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nSALBUTAMOL SULPHATE IP
\nEQ. TO SALBUTAMOL 2 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
525<\/td>SALBUTAMOL TABLETS IP 4 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nSALBUTAMOL SULPHATE IP
\nEQ. TO SALBUTAMOL 4 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
526<\/td>RANITIDINE & DOMPERIDONE
\nTABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nRANITIDINE HYDROCHLORIDE IP
\nEQ. TO RANITIDINE 150 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: SUSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
527<\/td>BROMHEXINE HYDROCHLORIDE, GUAIPHENESIN
\nPARACETAMOL, CHLORPHENIRAMINE MALEATE,
\n PHENYLEPHRINE HYDROCHLORIDE & TABLETS <\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 325 MG
\nBROMHEXINE HYDROCHLORIDE IP 8 MG
\nCHLORPHENIRAMINE MALEATE IP 2 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 10 MG
\nGUAIPHENESIN IP 100 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
528<\/td>DISULFIRAM TABLETS IP 500 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nDISULFIRAM IP 500 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
529<\/td>AZELNIDIPINE TABLETS IP 8 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nAZELNIDIPINE IP 8 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
530<\/td>FURAZOLIDONE & METRONIDAZOLE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nFURAZOLIDONE IP 100 MG
\nMETRONIDAZOLE IP 200 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
531<\/td>INDOMETHACIN CAPSULE IP 25 MG <\/td>EACH HARD GELATIN CAPSULE CONTAINS :
\nINDOMETHACIN IP 25 MG
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
532<\/td>SILDENAFIL CITRATE AND DAPOXETINE
\n HYDROCHLORIDE TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS :
\nSILDENAFIL CITRATE IP
\nEQ. TO SILDENAFIL 50 MG
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 30 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
533<\/td>PARACETAMOL, PHENYLEPHRINE HYDROCHLORIDE,
\nCETIRIZINE HYDROCHLORIDE, SODIUM CITRATE,
\nDEXTROMETHORPHAN HYDROBROMIDE &
\n MENTHOL SUSPENSION<\/td>		EACH 5 ML CONTAINS
\nPARACETAMOL IP 250 MG
\nPHENYLEPHRINE HYDROCHLORIDE IP 5 MG
\nCETIRIZINE HYDROCHLORIDE IP 2.5 MG
\nSODIUM CITRATE IP 25 MG
\nDEXTROMETHORPHAN HYDROBROMIDE IP 5 MG
\nMENTHOL IP 1 MG
\nFLAVOURED PALATABLE BASE Q.S.
\nCOLOUR: SUNSET YELLOW FCF
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
534<\/td>NIMESULIDE FLAVOURED DISPERSIBLE TABLETS 100 MG<\/td>EACH UNCOATED DISPERSIBLE TABLETS CONTAINS
\nNIMESULIDE BP 100 MG
\nEXCIPIENTS Q.S.
\n NOT FOR USE BELOW 12 YEARS OF AGE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
535<\/td>DAPOXETINE HYDROCHLORIDE IP 60 MG AND
\n SILDENAFIL CITRATE IP 100 MG TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 60 MG
\nSILDENAFIL CITRATE IP
\nEQ. TO SILDENAFIL 100 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE & TARTRAZINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
536<\/td>SPIRONOLACTONE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nSPIRONOLACTONE IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
537<\/td>TORSEMIDE TABLETS IP 10 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nTORSEMIDE IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
538<\/td>NIFEDIPINE SR TABLETS IP 20 MG<\/td>EACH FILM COATED SUSTAINED RELEASE TABLET CONTAINS
\nNIFEDIPINE IP 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td>NOV. 1989<\/td><\/td>\n<\/tr>\n
539<\/td>TORSEMIDE & SPIRONOLACTONE
\nTABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nTORSEMIDE IP 10 MG
\nSPIRONOLACTONE IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
540<\/td>CHLORTHALIDONE TABLETS IP<\/td>EACH FILM COATED SUSTAINED RELEASE TABLET CONTAINS
\nCHLORTHALIDONE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
541<\/td>CHLORTHALIDONE, TELMISARTAN &
\n AMLODIPINE TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS
\nCHLORTHALIDONE IP 6.25 MG
\nTELMISARTAN IP 40 MG
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
542<\/td>AMLODIPINE AND CHLORTHALIDONE TABLETS<\/td>EACH FILM TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nCHLORTHALIDONE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
543<\/td>NAPROXEN SODIUM & DOMPERIDONE TABLETS<\/td>EACH FILM COATED BILAYER TABLET CONTAINS
\nNAPROXEN SODIUM BP 500 MG
\nDOMPERIDONE MALEATE IP
\nEQ. TO DOMPERIDONE 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
544<\/td>AMISULPRIDE TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nAMISULPRIDE IP 200 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>12.03.10<\/td><\/td>\n<\/tr>\n
545<\/td>ETODOLAC EXTENDED RELEASE
\nTABLETS IP<\/td>		EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\n ETODOLAC 600 MG
\n EXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
546<\/td>TOLPERISONE HYDROCHLORIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nTOLPERISONE HYDROCHLORIDE 150 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE
\n<\/td>		<\/td>01.10.2008<\/td><\/td>\n<\/tr>\n
547<\/td>DAPOXETINE HYDROCHLORIDE IP TABLETS 30 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE & TARTRAZINE
\n<\/td>		IP<\/td>15.11.2010<\/td><\/td>\n<\/tr>\n
548<\/td>DAPOXETINE HYDROCHLORIDE IP TABLETS 60<\/td>EACH FILM COATED TABLET CONTAINS
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 60 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE & TARTRAZINE
\n<\/td>		IP<\/td>15.11.2010<\/td><\/td>\n<\/tr>\n
549<\/td>PARACETAMOL, PHENYLEPHRINE HCL, CAFFEINE AND DIPHENHYDRAMINE HCL TABLETS<\/td>EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE HCL IP 10 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE HCL IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>13.10.2010<\/td><\/td>\n<\/tr>\n
550<\/td>SUCRALFATE &
\nOXETACAINE SUSPENSION
\n<\/td>		EACH 5 ML CONTAINS
\nSUCRALFATE IP 500 MG
\nOXETACAINE BP 10 MG
\nFLAVOURED SYRUPY BASE Q.S
\n<\/td>		<\/td>KOKATE SR. 112
\n17.07.2015
\n<\/td>		<\/td>\n<\/tr>\n
551<\/td>SILVER SULFADIAZINE & CHLORHEXIDINE
\nGLUCONATE CREAM <\/td>		COMPOSITION
\nSILVER SULFADIAZINE IP 1.00 % W\/W
\nCHLORHEXIDINE GLUCONATE
\nSOLUTION IP 0.20 % W\/W
\nCHLOROCRESOL IP 0.10 % W\/W
\n(AS PRESERVATIVE)
\nCREAM BASE Q.S.
\n<\/td>		<\/td>06.07.2017<\/td><\/td>\n<\/tr>\n
552<\/td>PARACETAMOL, PHENYLEPHRINE HCL, CAFFEINE
\nAND DIPHENHYDRAMINE HCL TABLETS<\/td>		EACH UNCOATED TABLET CONTAINS
\nPARACETAMOL IP 500 MG
\nPHENYLEPHRINE HCL IP 10 MG
\nCAFFEINE (ANHYDROUS) IP 30 MG
\nDIPHENHYDRAMINE HCL IP 25 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
553<\/td>BACLOFEN EXTENDED RELEASE CAPSULES <\/td>EACH EXTENDED RELEASE (GRS) CAPSULE CONTAINS
\nBACLOFEN IP 30 MG
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL.
\n<\/td>		<\/td>01.08.2006<\/td><\/td>\n<\/tr>\n
554<\/td>BETAHISTINE HCl TABLETS IP 16 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nBETAHISTINE HYDROCHLORIDE IP 16 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>20.01.2000<\/td><\/td>\n<\/tr>\n
555<\/td>RABEPRAZOLE (EC) & ITOPRIDE
\n HYDROCHLORIDE (SR) CAPSULES
\n<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nRABEPRAZOLE SODIUM IP 20 MG
\n(AS ENTERIC COATED PELLETS)
\nITOPRIDE HYDROCHLORIDE IP 150 MG
\n(AS SUSTAINED RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL & PELLETS.
\n<\/td>		<\/td>28.11.2006<\/td><\/td>\n<\/tr>\n
556<\/td>ESOMEPRAZOLE ENTERIC COATED AND
\nLEVOSULPIRIDE SUSTAINED-RELEASE CAPSULES <\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nLEVOSULPIRIDE IP 75 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELL AND PELLETS
\n<\/td>		<\/td>13.02.2014<\/td><\/td>\n<\/tr>\n
557<\/td>ERGOTAMINE TARTRATE, CAFFEINE, PARACETAMOL
\n & PROCHLORPERAZINE MALEATE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\n ERGOTAMINE TARTRATE IP 1 MG
\nCAFFEINE (MONOHYDRATE) IP 100 MG
\nPARACETAMOL IP 250 MG
\nPROCHLORPERAZINE MALEATE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
558<\/td>DEXTROMETHORPHAN
\nHYDROBROMIDE, CHLORPHENIRAMINE MALEATE & MENTHOL SYRUP
\n<\/td>		EACH 5 ML CONTAINS
\nDEXTROMETHORPHAN HYDROBROMIDE IP 10 MG
\nCHLORPHENIRAMINE MALEATE IP 4 MG
\nMENTHOL IP 2 MG
\nFLAVOURED SYRUPY BASE Q.S.
\n COLOUR: SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
559<\/td>BISOPROLOL FUMARATE & AMLODIPINE
\nBESYLATE TABLETS<\/td>		EACH UNCOATED TABLET CONTAIN
\nBISOPROLOL FUMARATE IP 2.5MG
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>22.07.2005<\/td><\/td>\n<\/tr>\n
560<\/td>BISOPROLOL FUMARATE & AMLODIPINE
\n BESYLATE TABLETS<\/td>		EACH UNCOATED TABLET CONTAIN
\nBISOPROLOL FUMARATE IP 5MG
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td>30.11.2005<\/td><\/td>\n<\/tr>\n
561<\/td>AMLODIPINE AND HYDROCHLOROTHIAZI-DE
\nTABLETS <\/td>		EACH UNCOATED TABLET CONTAIN
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>14.04.2004<\/td><\/td>\n<\/tr>\n
562<\/td>CILNIDIPINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nCILNIDIPINE IP 5 MG
\nEXCIPIENTS Q.S
\nCOLOUR : IRON OXIDE YELLOW & TITANIUM DIOXIDE
\n<\/td>		IP<\/td>21.06.2007<\/td><\/td>\n<\/tr>\n
563<\/td>CILNIDIPINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nCILNIDIPINE IP 10 MG
\nEXCIPIENTS Q.S
\nCOLOUR : IRON OXIDE YELLOW & TITANIUM DIOXIDE
\n<\/td>		IP<\/td>21.06.2007<\/td><\/td>\n<\/tr>\n
564<\/td>CILNIDIPINE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nCILNIDIPINE IP 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : TITANIUM DIOXIDE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
565<\/td>ATORVASTATIN TABLETS IP 40 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 40 MG
\nEXCIPIENTS Q.S
\nCOLOUR : TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>17.09.1999<\/td><\/td>\n<\/tr>\n
566<\/td>ATORVASTATIN AND ASPIRIN CAPSULES<\/td>EACH HARD GELATIN CAPSULE CONTAINS:
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 10 MG
\nASPIRIN IP 75 MG
\n(AS GASTRO RESISTANT TABLLET)
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS
\n<\/td>		<\/td>18.01.2008<\/td><\/td>\n<\/tr>\n
567<\/td>ATORVASTATIN 10 MG AND
\nFENOFIBRATE 160 MG IP TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS:
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 10 MG
\nFENOFIBRATE IP 160 MG
\nCOLOUR: LAKE INDIGO CARMINE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>24.12.2004<\/td><\/td>\n<\/tr>\n
568<\/td>ATORVASTATIN AND CLOPIOGREL TABLETS <\/td>EACH UNCOATED BILAYER TABLET CONTAINS :
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 10MG
\nCLOPIOGREL BISULPHATE IP
\nEQ. TO CLOPIOGREL 75MG
\nEXCIPIENT Q.S.
\nCOLOUR : RED OXIDE OF IRON
\n<\/td>		<\/td>KOKATE SR. 2189
\n13.10.2016
\n<\/td>		<\/td>\n<\/tr>\n
569<\/td>LOSARTAN & HYDROCHLORO-THIAZIDE
\nTABLETS IP<\/td>		EACH FILM COATED TABLET CONTAINS:
\nLOSARTAN POTASSIUM IP 50 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>08.06.1999<\/td><\/td>\n<\/tr>\n
570<\/td>ROSUVASTATIN TABLETS IP 40 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSVASTATIN 40 MG
\nEXCIPIENTS Q.S.
\nCOLOURS : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>08.11.2008<\/td><\/td>\n<\/tr>\n
571<\/td>ROSUVASTATIN AND FENOFIBRATE TABLETS IP <\/td>EACH FILM COATED TABLET CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSVASTATIN 10 MG
\nFENOFIBRATE IP 160 MG
\nEXCIPIENTS Q.S.
\nCOLOURS : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>29.12.2010<\/td><\/td>\n<\/tr>\n
572<\/td>ROSUVASTATIN AND FENOFIBRATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSVASTATIN 20 MG
\nFENOFIBRATE IP 160 MG
\nEXCIPIENTS Q.S.
\nCOLOURS : TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>23.08.2010<\/td><\/td>\n<\/tr>\n
573<\/td>METOPROLOL SUCCINATE EXTENDED
\nRELEASE TABLET IP 12.5 MG<\/td>		EACH FILM COATED EXTENDED RELEASE TABLET CONTAIN :
\nMETOPROLOL SUCCINATE IP 11.875 MG
\nEQ. TO METOPROLOL TARTRATE 12.5 MG
\nEXCIPIENT Q.S.
\n COLOUR : RED OXIDE OF IRON & TITANIUM DIOXIDE
\n<\/td>		IP<\/td>15.04.2005<\/td><\/td>\n<\/tr>\n
574<\/td>METOPROLOL PROLONGED RELEASE TABLETS IP<\/td>EACH FILM COATED PROLONGED RELEASE TABLET CONTAIN :
\nMETOPROLOL SUCCINATE IP 23.75 MG
\nEQ. TO METOPROLOL TARTRATE 25 MG
\nEXCIPIENT Q.S.
\n COLOUR : TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>30.10.2002<\/td><\/td>\n<\/tr>\n
575<\/td>METOPROLOL PROLONGED RELEASE TABLETS IP<\/td>EACH FILM COATED PROLONGED RELEASE TABLET CONTAIN
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\nEXCIPIENT Q.S.
\n COLOUR : TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>30.10.2002<\/td><\/td>\n<\/tr>\n
576<\/td>TENELIGLIPTIN TABLETS 20 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nTENELIGLIPTIN HYDROBROMIDE HYDRATE IP
\nEQ. TO TENELIGLIPTIN 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		<\/td>18.05.2015<\/td><\/td>\n<\/tr>\n
577<\/td>METFORMIN HYDROCHLORIDE SUSTAINED
\nRLEASE TABLET IP<\/td>		EACH UNCOATED SUSTAINED RELEASE TABLET CONTAIN :
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\nEXCIPIENTS
\n<\/td>		IP<\/td>2002<\/td><\/td>\n<\/tr>\n
578<\/td>VOGLIBOSE, GLIMEPIRIDE AND
\nMETFORMIN HYDROCHLORIDE (SUSTAINED RELEASE) TABLETS
\n<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS:
\nVOGLIBOSE IP 0.3 MG
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE USPNF YELLOW & FERRIC OXIDE USP NF RED
\n<\/td>		<\/td>14.01.2020<\/td><\/td>\n<\/tr>\n
579<\/td>VOGLIBOSE, GLIMEPIRIDE AND
\nMETFORMIN HYDROCHLORIDE (SUSTAINED RELEASE) TABLETS
\n<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS:
\nVOGLIBOSE IP 0.2 MG
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE USPNF YELLOW & FERRIC OXIDE USP NF RED
\n<\/td>		<\/td>14.01.2020<\/td><\/td>\n<\/tr>\n
580<\/td>VOGLIBOSE TABLET IP 0.2 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nVOGLIBOSE IP 0.2 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>17.11.2005<\/td><\/td>\n<\/tr>\n
581<\/td>VOGLIBOSE TABLET IP 0.3 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nVOGLIBOSE IP 0.3 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>17.11.2005<\/td><\/td>\n<\/tr>\n
582<\/td>RAMIPRIL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS:
\nRAMIPRIL IP 2.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW IRON OXIDE
\n<\/td>		IP<\/td>2005<\/td><\/td>\n<\/tr>\n
583<\/td>RAMIPRIL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS:
\nRAMIPRIL IP 5 MG
\nEXCIPIENTS Q.S
\n<\/td>		IP<\/td>2005<\/td><\/td>\n<\/tr>\n
584<\/td>VILDAGLIPTIN AND METFORMIN
\nHYDROCHLORIDE TABLET<\/td>		EACH FILM COATED TABLET CONTAINS
\nVILDAGLIPTIN IP 50 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP & YELLOW OXIDE OF IRON
\n<\/td>		<\/td>21.07.2008<\/td><\/td>\n<\/tr>\n
585<\/td>SITAGLIPTIN PHOSPHATE AND METFORMIN
\n HYDROCHLORIDE TABLET<\/td>		EACH FILM COATED TABLET CONTAINS
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP 64.25MG
\nEQ. TO SITAGLIPTIN 50 MG
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP & RED OXIDE OF IRON
\n<\/td>		<\/td>28.04.2008<\/td><\/td>\n<\/tr>\n
586<\/td>SITAGLIPTIN PHOSPHATE AND METFORMIN
\nHYDROCHLORIDE TABLET<\/td>		EACH FILM COATED TABLET CONTAINS
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP 64.25 MG
\n EQ. TO SITAGLIPTIN 50 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP & RED OXIDE OF IRON
\n<\/td>		<\/td>28.04.2008<\/td><\/td>\n<\/tr>\n
587<\/td>BISOPROLOL FUMARATE TABLET USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE IP 2.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>19.01.2001<\/td><\/td>\n<\/tr>\n
588<\/td>BISOPROLOL FUMARATE TABLET USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE IP 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>27.02.1992<\/td><\/td>\n<\/tr>\n
589<\/td>BISOPROLOL FUMARATE TABLET USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE IP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>27.02.1992<\/td><\/td>\n<\/tr>\n
590<\/td>DOXOFYLLINE AND AMBROXOL
\nHYDROCHLORIDE TABLETS <\/td>		EACH UNCOATED TABLET CONTAINS
\nDOXOFYLLINE IP 400 MG
\nAMBROXOL HYDROCHLORIDE IP 30 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>23.12.2009<\/td><\/td>\n<\/tr>\n
591<\/td>DICLOFENAC SODIUM & PARACETAMOL TABLETS<\/td>EACH UNCOATED TABLET CONTAINS:
\nDICLOFENAC SODIUM IP 50 MG
\nPARACETAMOL IP 250 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
592<\/td>PARACETAMOL AND CAFFEINE TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS:
\nPARACETAMOL IP 500 MG
\nCAFFEINE IP
\nEQ. ANHYDROUS CAFFEINE 50 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
593<\/td>TELMISARTAN TABLET IP 80 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nTELMISARTAN IP 80 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>14.05.2010<\/td><\/td>\n<\/tr>\n
594<\/td>GLIMEPIRIDE TABLET IP 3 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nGLIMEPIRIDE IP 3 MG
\nEXCIPIENT Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON
\n<\/td>		IP<\/td>24.01.1999<\/td><\/td>\n<\/tr>\n
595<\/td>GLIMEPIRIDE TABLET IP 4 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nGLIMEPIRIDE IP 4MG
\nEXCIPIENT Q.S.
\nCOLOUR: QUINOLINE YELLOW
\n<\/td>		IP<\/td>24.01.1999<\/td><\/td>\n<\/tr>\n
596<\/td>RABEPRAZOLE SODIUM TABLET 40 MG<\/td>EACH ENTERIC COATED TABLET CONTAINS:
\nRABEPRAZOLE SODIUM IP 40 MG
\nCOLOUR : YELLOW OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
597<\/td>GLIMEPIRIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLIMEPIRIDE IP 3 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
598<\/td>GLIMEPIRIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS
\nGLIMEPIRIDE IP 4 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
599<\/td>GLIMEPIRIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH FILM COATED TABLETS CONTAINS
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HYDROCHLORIDE IP 850 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
600<\/td>GLIMEPIRIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH FILM COATED TABLETS CONTAINS
\nGLIMEPIRIDE IP 3 MG
\nMETFORMIN HYDROCHLORIDE IP 850 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
601<\/td>GLIMEPIRIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH FILM COATED TABLETS CONTAINS
\nGLIMEPIRIDE IP 4 MG
\nMETFORMIN HYDROCHLORIDE IP 850 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
602<\/td>PIOGLITAZONE HYDROCHLORIDE TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 15 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>17.10.2000<\/td><\/td>\n<\/tr>\n
603<\/td>PIOGLITAZONE HYDROCHLORIDE TABLET IP<\/td>EACH UNCOATED TABLET CONTAINS
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON
\n<\/td>		IP<\/td>17.10.2000<\/td><\/td>\n<\/tr>\n
604<\/td>PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (SR) TABLET<\/td>EACH UNCOATED TABLET CONTAINS
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 15 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
605<\/td>DICLOFENAC SODIUM SUSTAINED RELEASE TABLET IP<\/td>EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 75MG
\nEXCIPIENTS Q.S.
\nCOLOUR : IRON OXIDE RED & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
606<\/td>DICLOFENAC SODIUM SUSTAINED RELEASE TABLET IP<\/td>EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS
\nDICLOFENAC SODIUM IP 150 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : IRON OXIDE RED & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
607<\/td>ROSUVASTATIN TABLET IP<\/td>EACH FILM COATED TABLET CONTAINS
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : FERRIC OXIDE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>08.11.2008<\/td><\/td>\n<\/tr>\n
608<\/td>ROSUVASTATIN TABLET IP<\/td>EACH FILM COATED TABLET CONTAINS
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : FERRIC OXIDE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>08.11.2008<\/td><\/td>\n<\/tr>\n
609<\/td>DAPAGLIFLOZIN TABLETS 10 MG <\/td>EACH FILM COATED TABLETS CONTAINS
\nDAPAGLIFLOZIN 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>25.02.2015<\/td><\/td>\n<\/tr>\n
610<\/td>PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (SR) TABLET<\/td>EACH UNCOATED TABLET CONTAINS:
\nPIOGLITAZONE HYDROCHLORIDE IP
\nEQ. TO PIOGLITAZONE 15 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN A SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON
\n<\/td>		<\/td>18.10.2002<\/td><\/td>\n<\/tr>\n
611<\/td>ROSUVASTATIN AND CLOPIDOGREL TABLET
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 10 MG
\nCLOPIDOGREL BISULPHATE IP
\nEQ. CLOPIDOGREL 75 MG
\nEXCIPIENT Q.S.
\nCOLOUR: FERRIC OXIDE & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
612<\/td>ROSUVASTATIN AND CLOPIDOGREL
\nTABLET
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 20 MG
\nCLOPIDOGREL BISULPHATE IP
\nEQ. CLOPIDOGREL 75 MG
\nEXCIPIENT Q.S.
\nCOLOUR: FERRIC OXIDE , TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
613<\/td>ATORVASTATIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS:
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE LAKE & TITANIUM
\nDIOXIDE IP
\n<\/td>		IP<\/td>30.10.2001<\/td><\/td>\n<\/tr>\n
614<\/td>ATORVASTATIN TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS::
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE LAKE & TITANIUM
\nDIOXIDE IP
\n<\/td>		IP<\/td>20.04.2011<\/td><\/td>\n<\/tr>\n
615<\/td>ATORVASTATIN & FENOFIBRATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS::
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 10 MG
\nFENOFIBRATE IP 160 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: LAKE INDIGO CARMINE & TITANIUM DIOXIDE IP
\n
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
616<\/td>ATORVASTATIN & FENOFIBRATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS: :
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 20 MG
\nFENOFIBRATE IP 160 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: LAKE INDIGO CARMINE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
617<\/td>ATORVASTATIN & FENOFIBRATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS: :
\nATORVASTATIN CALCIUM IP
\nEQ. TO ATORVASTATIN 40 MG
\nFENOFIBRATE IP 160 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: LAKE INDIGO CARMINE & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
618<\/td>BISOPROLOL FUMARATE TABLETS USP<\/td>EACH FILM COATED TABLET CONTAINS:
\nBISOPROLOL FUMARATE USP 5 MG
\nCOLOUR : FERRIC OXIDE USP NF& TITANIUM DIOXIDE IP
\n
\n<\/td>		USP<\/td>27.02.1992<\/td><\/td>\n<\/tr>\n
619<\/td>BISOPROLOL FUMARATE TABLETS USP<\/td>EACH FILM COATED TABLET CONTAINS:
\nBISOPROLOL FUMARATE USP 2.5 MG
\nCOLOUR : FERRIC OXIDE USP NF& TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>13.05.1999<\/td><\/td>\n<\/tr>\n
620<\/td>DRIED ALUMINIUM HYDROXIDE, MAGNESIUM ALUMINIUM SILICATE HYDRATE,
\n MAGNESIUM HYDROXIDE & SIMETHICONE TABLETS<\/td>		EACH UNCOATED CHEWABLE TABLET CONTAINS:
\nDRIED ALUMINIUM HYDROXIDE GEL IP 300 MG
\nMAGNESIUM ALUMINIUM SILICATE
\nHYDRATE 50 MG
\nMAGNESIUM HYDROXIDE IP 25 MG
\nSIMETHICONE IP 25 MG
\nCOLOUR :SUNSET YELLOW FCF
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
621<\/td>ASPIRIN GASTRO-RESISTANT TABLET IP 75 MG <\/td>EACH GASTRO-RESISTANT TABLET CONTAINS::
\nASPIRIN IP 75 MG
\nCOLOUR: LAKE OF SUNSET YELLOW FCF &
\nTITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
622<\/td>FOLIC ACID TABLET IP 5 MG<\/td>EACH UNCOATED TABLET CONTAINS:
\nFOLIC ACID IP 5 MG
\nEXCIPIENT Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
623<\/td>HYDROXYCHLOROQUINE TABLETS IP
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nHYDROXYCHLOROQUINE SULPHATE IP 200 MG
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
624<\/td>NIFEDIPINE SUSTAINED RELEASE TABLETS IP 30 MG <\/td>EACH FILM COATED SUSTAINED RELEASE TABLET CONTAINS
\nNIFEDIPINE IP 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
625<\/td>NIFEDIPINE SUSTAINED RELEASE TABLET IP 10 MG<\/td>EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS:
\nNIFEDIPINE IP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW FCF
\n<\/td>		IP<\/td>DEC.1984<\/td><\/td>\n<\/tr>\n
626<\/td>NIFEDIPINE SUSTAINED RELEASE TABLET IP 60 MG
\n<\/td>		EACH SUSTAINED RELEASE FILM COATED TABLET CONTAINS:
\nNIFEDIPINE IP 60 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW FCF
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
627<\/td>SILVER NITRATE GEL 0.2% W\/W
\n<\/td>		COMPOSITION:
\nSILVER NITRATE IP 0.2% W\/W
\nETHYL ALCOHOL IP 4% V\/V
\nGEL BASE Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
628<\/td>NANOCRYSTALLINE SILVER GEL
\n<\/td>		COMPOSITION:
\nEACH GRAM OF GEL CONTAINS:
\nSILVER AS NANO PARTICLES 0.002 %
\nPERFUMED GEL BASE Q.S.
\nCOLOUR: CARMOISINE
\n<\/td>		<\/td>04.01.2008<\/td><\/td>\n<\/tr>\n
629<\/td>SILDENAFIL CITRATE
\nAND DAPOXETINE
\n HYDROCHLORIDE TABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nSILDENAFIL CITRATE IP
\nEQ. TO SILDENAFIL 50 MG
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: BRILLIANT BLUE LAKE, QUINOLINE YELLOW LAKE, IRON OXIDE BLACK & TITANIUM DIOXIDE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
630<\/td>TADALAFIL
\nAND DAPOXETINE
\n HYDROCHLORIDE TABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nTADALAFIL IP 10 MG
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 30 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
631<\/td>OMEPRAZOLE MAGNESIUM & DOMPERIDONE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS:
\nOMEPRAZOLE MAGNESIUM IP
\nEQ TO OMEPRAZOLE 20 MG
\nDOMPERIDONE IP 10 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
632<\/td>GLIBENCLAMIDE & METFORMIN HYDROCHLORIDE
\n(SR) TABLETS IP
\n<\/td>		EACH UNCOATED BILAYERED TABLETS CONTAINS:
\nGLIBENCLAMIDE IP 2.5 MG
\nMETFORMIN HYDROCHLORIDE IP 400 MG
\nEXCIPIENTS Q.S
\nCOLOUR : RED OXIDE OF IRON
\n<\/td>		IP<\/td>26.11.1996 <\/td><\/td>\n<\/tr>\n
633<\/td>ATORVASTATIN, CLOPIDOGREL
\nAND ASPIRIN CAPSULES
\n<\/td>		EACH HARD GELATIN CAPSULE CONTAINS:
\nATORVASTATIN CALCIUM IP (AS PELLETS)
\nEQ. TO ATORVASTATIN 20 MG
\nCLOPIDOGREL BISULPHATE IP (AS PELLETS)
\nEQ. TO CLOPIDOGREL 75 MG
\nASPIRIN IP 75 MG
\n(AS GASTRO-RESISTANT PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
634<\/td>PARACETAMOL EXTENDED RELEASE TABLETS 650 MG <\/td>EACH UNCOATED BILAYERED TABLET CONTAINS:
\nPARACETAMOL IP 325 MG
\n(AS IMMEDIATE RELEASE)
\nPARACETAMOL IP 325 MG
\n(AS EXTENDED RELEASE)
\nAPPROVED COLOUR USED
\n<\/td>		<\/td>1996<\/td><\/td>\n<\/tr>\n
635<\/td>SILODOSIN 8 MG TABLETS <\/td>EACH FILM COATED TABLET CONTAINS:
\nSILODOSIN 8 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: LAKE SUNSET YELLOW FCF
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
636<\/td>LEVOCETIRIZINE DIHYDROCHLORIDE DISPERSIBLE TABLETS<\/td>EACH UNCOATED DISPERSIBLE TABLET CONTAINS:
\nLEVOCETIRIZINE HYDROCHLORIDE IP 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>27.07.2007<\/td><\/td>\n<\/tr>\n
637<\/td>METHYLPREDNISOLONE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nMETHYLPREDNISOLONE IP 4 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
638<\/td>SAXAGLIPTIN TABLETS 5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nSAXAGLIPTIN HYDROCHLORIDE
\nEQ. TO SAXAGLIPTIN 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
639<\/td>SAXAGLIPTIN TABLETS 2.5 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nSAXAGLIPTIN HYDROCHLORIDE
\nEQ. TO SAXAGLIPTIN 2.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON & TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
640<\/td>TAPENTADOL HYDROCHLORIDE TABLETS<\/td>EACH FILM COATED TABLETS CONTAINS
\nTAPENTADOL HYDROCHLORIDE
\nEQ. TO TAPENTADOL 100 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW FCF
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
641<\/td>ACECLOFENAC, LINSEED OIL,MENTHOL , METHYL
\nSALICYLATE & CAPSAICIN GEL
\n<\/td>		COMPOSITION
\nACECLOFENAC BP 1.5% W\/W
\nLINSEED OIL (OLEUM LINI) BP 3.00% W\/W
\nMENTHOL BP 5.00% W\/W
\nMETHYL SALICYLATE BP 10.00% W\/W
\nCAPSAICIN USP 0.025%W\/W
\nBENZYL ALCOHOL BP 0.1 % W\/W
\nGEL BASE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
642<\/td>AMITRIPTYLINE HYDROCHLORIDE AND CHLORDIAZEPOXIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nAMITRIPTYLINE HYDROCHLORIDE IP
\nEQ TO AMITRIPTYLINE 12.5 MG
\nCHLORDIAZEPOXIDE IP 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
643<\/td>TELMISARTAN AND METOPROLOL SUCCINATE
\nPROLONGED-RELEASE TABLETS
\n<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nMETOPROLOL SUCCINATE IP 47.5 MG
\nEQ. TO METOPROLOL TARTRATE 50 MG
\n(AS PROLONGED-RELEASE)
\nEXCIPIENTS Q.S.
\n COLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
644<\/td>TELMISARTAN AND METOPROLOL SUCCINATE
\nPROLONGED-RELEASE TABLETS
\n<\/td>		EACH UNCOATED BILAYERED TABLET CONTAINS
\nTELMISARTAN IP 40 MG
\nMETOPROLOL SUCCINATE IP 23.75 MG
\nEQ. TO METOPROLOL TARTRATE 25 MG
\n(AS PROLONGED-RELEASE)
\nEXCIPIENTS Q.S.
\n COLOUR: YELLOW OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
645<\/td>AMITRIPTYLINE HYDROCHLORIDE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nAMITRIPTYLINE HYDROCHLORIDE IP
\nEQ TO AMITRIPTYLINE 75 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
646<\/td>ESOMEPRAZOLE TABLETS
\n(WITH SODIUM BICARBONATE AS BUFFER)
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nESOMEPRAZOLE MAGNESIUM TRIHYDRATE IP
\nEQ. TO ESOMEPRAZOLE 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td>14.05.2008<\/td><\/td>\n<\/tr>\n
647<\/td>PANTOPRAZOLE & DOMPERIDONE MALEATE TABLETS<\/td>EACH ENTERIC COATED TABLET CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQ. TO PANTOPRAZOLE 40 MG
\nDOMPERIDONE MALEATE IP
\nEQ. TO DOMPERIDONE 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: YELLOW OXIDE OF IRON
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
648<\/td>PANTOPRAZOLE & DOMPERIDONE CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nPANTOPRAZOLE SODIUM IP
\nEQ. TO PANTOPRAZOLE 40 MG
\n(AS ENTERIC COATED) PELLETS
\nDOMPERIDONE MALEATE IP
\nEQ. TO DOMPERIDONE 30 MG
\n(10 MG IMMEDIATE RELEASE AND 20 MG AS SUSTAINED RELEASE)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
649<\/td>RAMIPRIL TABLETS IP 10 MG <\/td>EACH UNCOATED TABLET CONTAINS:
\nRAMIPRIL IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>2005<\/td><\/td>\n<\/tr>\n
650<\/td>CARVEDILOL PHOSPHATE EXTENDED RELEASE TABLETS <\/td>EACH UNCOATED EXTENDED RELEASE TABLETS CONTAINS:
\nCARVEDILOL PHOSPHATE 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td>11.12.2009<\/td><\/td>\n<\/tr>\n
651<\/td>CARVEDILOL PHOSPHATE EXTENDED RELEASE TABLETS <\/td>EACH UNCOATED EXTENDED RELEASE TABLETS CONTAINS:
\nCARVEDILOL PHOSPHATE 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: QUINOLINE YELLOW LAKE
\n<\/td>		<\/td>11.12.2009<\/td><\/td>\n<\/tr>\n
652<\/td>AMISULPRIDE TABLETS IP 400 MG<\/td>EACH FILM COATED TABLET CONTAINS:
\nAMISULPRIDE IP 400 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW LAKE
\n<\/td>		IP<\/td>12.03.10<\/td><\/td>\n<\/tr>\n
653<\/td>DICLOFENAC SODIUM TABLETS IP<\/td>EACH ENTERIC COATED TABLET CONTAINS:
\nDICLOFENAC SODIUM IP 50 MG
\nEXCIEPINTS Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
654<\/td>CHLORTHALIDONE 6.25 MG & METOPROLOL SUCCINATE EXTENDED
\nRELEASE 25 MG TABLETS <\/td>		EACH FILM COATED BILAYERED TABLETS CONTAINS
\nCHLORTHALIDONE IP 6.25 MG
\nMETOPROLOL SUCCINATE IP 23.75 MG
\nEQ. TO METOPROLOL TARTRATE 25 MG
\n(AS EXTENDED RELEASE PART)
\nCOLOUR: INDIGO CARMINE & QUINOLINE YELLOW WS
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
655<\/td>NIFEDIPINE EXTENDED RELEASE TABLETS USP 60 MG<\/td>EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\nNIFEDIPINE USP 60 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE YELLOW USP & TITANIUM DIOXIDE BP
\n<\/td>		USP<\/td><\/td><\/td>\n<\/tr>\n
656<\/td>TADALAFIL
\nAND DAPOXETINE
\n HYDROCHLORIDE
\nTABLETS
\n<\/td>		EACH FILM COATED TABLET CONTAINS:
\nTADALAFIL IP 20 MG
\nDAPOXETINE HYDROCHLORIDE IP
\nEQ. TO DAPOXETINE 30 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:QUINOLINE YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
657<\/td>RAMIPRIL AND AMLODIPINE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nRAMIPRIL IP 2.5 MG
\nAMLODIPINE BESYLATE IP
\nEQUIVALENT TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:TITANIUM DIOXIDE BP
\n<\/td>		<\/td>04.10.2004<\/td><\/td>\n<\/tr>\n
658<\/td>RAMIPRIL & HYDROCHLOROTHIAZIDE TABLETS <\/td>EACH UNCOATED TABLET CONTAINS
\nRAMIPRIL IP 5 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
659<\/td>MODAFINIL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nMODAFINIL IP 100 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>16.12.2003<\/td><\/td>\n<\/tr>\n
660<\/td>TORSEMIDE TABLETS IP 40 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nTORSEMIDE IP 40 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
661<\/td>TORSEMIDE TABLETS IP 100 MG<\/td>EACH UNCOATED TABLET CONTAINS
\nTORSEMIDE IP 100 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
662<\/td>CINITAPRIDE TABLETS 1 MG <\/td>EACH UNCOATED TABLET CONTAINS
\nCINITAPRIDE HYDROGEN TARTRATE
\nEQUIVALENT TO CINITAPRIDE 1 MG
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td>1\/4\/2008<\/td><\/td>\n<\/tr>\n
663<\/td>OLMESARTAN MEDOXOMIL AND CHLORTHALIDONE TABLETS <\/td>EACH FILM COATED BILAYERED TABLET CONTAINS
\nOLMESARTAN MEDOXOMIL IP 40 MG
\nCHLORTHALIDONE IP 6.25 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
664<\/td>OLMESARTAN AND CHLORTHALIDONE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCHLORTHALIDONE IP 12.5 MG
\nOLMESARTAN MEDOXOMIL IP 40 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:PONCEAU 4R
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
665<\/td>OLMESARTAN AND CHLORTHALIDONE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCHLORTHALIDONE IP 12.5 MG
\nOLMESARTAN MEDOXOMIL IP 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:QUINOLINE YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
666<\/td>CHLORTHALIDONE AND OLMESARTAN MEDOXOMIL TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCHLORTHALIDONE IP 6.25 MG
\nOLMESARTAN MEDOXOMIL IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
667<\/td>CILNIDIPINE AND OLMESARTAN MEDOXOMIL TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nCILNIDIPINE IP 10 MG
\nOLMESARTAN MEDOXOMIL IP 20 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
668<\/td>CARBIMAZOLE TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nCARBIMAZOLE IP 5 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
669<\/td>PARACETAMOL IMMEDIATE RELEASE 300 MG & SUSTAINED RELEASE 700 MG <\/td>EACH UNCOATED BIAYERED TABLET PARACETAMOL IP 300 MG
\n(AS IMMEDIATE RELEASE)
\nPARACETAMOL IP 700 MG
\n(AS SUSTAINED RELEASE)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
670<\/td>MINOXIDIL TOPICAL SOLUTION USP 10% W\/V<\/td>COMPOSITION
\nMINOXIDIL IP 10.0%W\/V
\nABSOLUTE ALCOHOL CONTENT 40.0%V\/V
\n<\/td>		USP<\/td><\/td><\/td>\n<\/tr>\n
671<\/td>FLUOXETINE HCL CAPSULES IP 60 MG<\/td>EACH HARD GELATINE CPASULES CONTAINS
\nFLUOXETINE HYDROCHLORIDE IP
\nEQUIVALENT TO FLUOXETINE 60 MG
\n<\/td>		IP<\/td>1990-MARCH<\/td><\/td>\n<\/tr>\n
672<\/td>BECLOMETHASONE DIPROPIONATE, PHENYLEPHRINE
\nHYDROCHLORIDE & LIDOCAINE HYDROCHLORIDE CREAM<\/td>		COMPOSITION:
\nBECLOMETHASONE DIPROPIONATE IP 0.025 % W\/W
\nPHENYLEPHRINE HYDROCHLORIDE IP 0.10W\/W
\nLIDOCAINE HYDROCHLORIDE IP 2.50%W\/W
\nCREAM BASE Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
673<\/td>RIVAROXABAN TABLETS 20 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nRIVAROXABAN 20 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:IRON OXIDE RED & TITANIUM DIOXIDE
\n<\/td>		<\/td>02.09.14<\/td><\/td>\n<\/tr>\n
674<\/td>RANOLAZINE EXTENDED RELEASE
\nTABLETS 1000 MG
\n<\/td>		EACH FILM COATED EXTENDED RELEASE TABLET CONTAINS
\nRANOLAZINE 1000 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:IRON OXIDE RED
\n<\/td>		<\/td>31.01.09<\/td><\/td>\n<\/tr>\n
675<\/td>EPLERENONE TABLETS <\/td>EACH FILM COATED TABLET CONTAINS
\nEPLERENONE IP 50 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
676<\/td>NICOUMALONE TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nNICOUMALONE IP 2 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
677<\/td>NICOUMALONE TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nNICOUMALONE IP 3 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:QUINOLINE YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
678<\/td>RANITIDINE HYDROCHLORIDE TABLETS IP <\/td>EACH FILM COATED TABLET CONTAINS
\nRANITIDINE HYDROCHLORIDE IP
\nEQUIVALENT TO RANITIDINE 300 MG
\nEXCIPIENTS Q.S.
\nCOLOUR:SUNSET YELLOW FCF & TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
679<\/td>BRIVARACETAM TABLETS 100 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nBRIVARACETAM 100 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
680<\/td>FAROPENEM TABLETS JP 200 MG<\/td>EACH FILM COATED TABLET CONTAINS
\nFAROPENEM SODIUM HYDRATE IP
\n EQUIVALENT TO FAROPENEM 200 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE USP NF RED FERRIC OXIDE USP NF YEW & TITANIUM DIOXIDE IP
\n<\/td>		JP<\/td>16.04.08<\/td><\/td>\n<\/tr>\n
681<\/td>GLIMEPRIDE,
\nVOGLIBOSE & METFORMIN HYDROCHLORIDE SUSTAINED RELEASE TABLETS
\n<\/td>		EACH FILM COATED BILAYERED SUSTAINED RELEASE TABLETS
\nGLIMEPRIDE IP 2 MG
\nVOGLIBOSE IP 0.2 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\n(IN SUSTAINED RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR :TITANIUM DIOXIDE & ERYTHROSINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
682<\/td>ACEBROPHYLLINE 100 MG + N-ACETYLCYSTEINE
\n600 MG TABLETS <\/td>		EACH FILM COATED BILAYERED TABLET CONTAINS
\nACEBROPHYLLINE 100 MG
\nN-ACETYLCYSTEINE BP 600 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : QUINOLINE YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
683<\/td>OLMESARTAN, AMLODIPINE &
\nHYDROCHLOROTHIAZIDE TABLETS <\/td>		EACH FILM COATED TABLET CONTAINS
\nOLMESARTAN MEDOXOMIL IP 20 MG
\nAMLODIPINE BESYLATE IP
\nEQ.TO AMLODIPINE 5 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
684<\/td>OLMESARTAN, AMLODIPINE &
\nHYDROCHLOROTHIAZIDE TABLETS<\/td>		EACH FILM COATED TABLET CONTAINS
\nOLMESARTAN MEDOXOMIL IP 40 MG
\nAMLODIPINE BESYLATE IP
\nEQ.TO AMLODIPINE 5 MG
\nHYDROCHLOROTHIAZIDE IP 12.5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR :SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
685<\/td>SILDENAFIL CITRATE TABLETS IP<\/td>EACH FILM COATED TABLET CONTAINS
\nSILDENAFIL CITRATE IP
\nEQ.TO SILDENAFIL 25 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : RED OXIDE OF IRON
\n<\/td>		IP<\/td>08.01.2001<\/td><\/td>\n<\/tr>\n
686<\/td>ZOLPIDEM TARTRATE TABLETS IP <\/td>EACH FILM COATED TABLET CONTAINS
\nZOLPIDEM TARTRATE IP 10 MG
\nEXCIPIENTS Q.S.
\nCOLOUR : TITANIUM DIOXIDE IP
\n<\/td>		IP<\/td>12.10.15<\/td><\/td>\n<\/tr>\n
687<\/td>ACECLOFENAC AND PARACETAMOL SUSPENSION <\/td>EACH 5 ML CONTAINS
\nACECLOFENAC IP 50 MG
\nPARACETAMOL IP 125 MG
\nFLAVOURED SYRUP BASE Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
688<\/td>TAMSULOSIN HYDROCHLORIDE
\n MODIFIED RELEASE TABLETS 0.4 MG
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nTAMSULOSIN HYDROCHLORIDE IP 0.4 MG
\n(AS MODIFIED RELEASE)
\nEXCIPIENTS Q.S.
\n COLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
689<\/td>PREGABALIN SUSTAINED RELEASE &
\nMETHYLCOBALAMIN TABLETS
\n<\/td>		EACH UNCOATED TABLETS CONTAINS
\nPREGABALIN IP 75 MG
\n(IN SUSTAINED RELEASE FORM)
\nMETHYLCOBALAMIN IP 750 MCG
\nEXCIPIENTS Q.S.
\n COLOUR: PONCEAU 4R LAKE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
690<\/td>DOXYLAMINE SUCCINATE 20 MG, PYRIDOXINE HYDROCHLORIDE 20 MG
\n & FOLIC ACID 5 MG TABLETS<\/td>		EACH ENTERIC COATED TABLET CONTAINS
\nDOXYLAMINE SUCCINATE BP 20 MG
\nPYRIDOXINE HYDROCHLORIDE IP 20 MG
\nFOLIC ACID IP 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
691<\/td>ALBENDAZOLE SUSPENSION IP<\/td>EACH 10 ML CONTAINS
\nALBENDAZOLE IP 400 MG
\nFLAVOURED SYRUPY BASE Q.S.
\nAPPROVED COLOUR USED
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
692<\/td>SILODOSIN CAPSULES <\/td>EACH HARD GELATIN CAPSULE CONTAINS
\nSILODOSIN 8 MG
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
693<\/td>PANTOPRAZOLE GASTRO-RESISTANT AND DOMPERIDONE
\nPROLONGED-RELEASE CAPSULES IP<\/td>		EACH HARD GELATIN CAPSULE CONTAINS
\nPANTOPRAZOLE SODIUM SESQUIHYDRATE IP
\nEQ. TO PANTOPRAZOLE 40 MG
\n(AS ENTERIC COATED PELLETS)
\nDOMPERIDONE IP 30 MG
\n(AS SUSTAINED-RELEASE PELLETS)
\nEXCIPIENTS Q.S.
\nAPPROVED COLOUR USED IN EMPTY HARD GELATIN CAPSULE SHELL AND PELLETS
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
694<\/td>ASPIRIN GASTRO-RESISTANT AND ROSUVASTATIN CALCIUM CAPSULES IP<\/td>EACH HARD GELATIN CAPSULE CONTAINS:
\nROSUVASTATIN CALCIUM IP
\nEQ. TO ROSUVASTATIN 10 MG ASPIRIN IP 75 MG
\n(AS ENTERIC COATED)
\nAPPROVED COLOUR USED IN EMPTY CAPSULES SHELLS
\n<\/td>		IP<\/td>30.03.11<\/td><\/td>\n<\/tr>\n
695<\/td>NICORANDIL TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nNICORANDIL IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>10.01.1997<\/td><\/td>\n<\/tr>\n
696<\/td>NICORANDIL TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nNICORANDIL IP 5 MG
\nEXCIPIENTS Q.S
\n<\/td>		IP<\/td>10.01.1997<\/td><\/td>\n<\/tr>\n
697<\/td>CLOPIDOGREL AND ASPIRIN TABLETS IP <\/td>EACH FILM COATED BILAYERED TABLET CONTAINS
\nCLOPIDOGREL BISULPHATE IP
\nEQ. TO CLOPIDOGREL 75 MG
\nASPIRIN IP 75 MG
\n(IN COATED FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: LAKE OF SUNSET YELLOW
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
698<\/td>CLOPIDOGREL AND ASPIRIN TABLETS IP <\/td>EACH FILM COATED BILAYERED TABLET CONTAINS
\nCLOPIDOGREL BISULPHATE IP
\nEQ. TO CLOPIDOGREL 75 MG
\nASPIRIN IP 150 MG
\n(IN COATED FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
699<\/td>BACLOFEN TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nBACLOFEN IP 10 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
700<\/td>BACLOFEN TABLETS IP <\/td>EACH UNCOATED TABLET CONTAINS
\nBACLOFEN IP 20 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td><\/td><\/td>\n<\/tr>\n
701<\/td>DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUSTAINED-RELEASE)
\nTABLETS<\/td>		EACH UNCOATED BILAYER TABLET CONTAINS
\nDAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE EQ. TO DAPAGLIFLOZIN 10 MG
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\n(IN SUSTAINED-RELEASE FORM)
\nEXCIPIENTS Q.S.
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
702<\/td>ARTEMETHER & LUMEFENTRINE FOR ORAL
\nSUSPENSION <\/td>		EACH 5 ML (AFTER RECONSTITUTION) CONTAINS
\nARTEMETHER IP 20 MG
\nLUMEFANTRINE USP 120 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: SUNSET YELLOW
\n<\/td>		<\/td><\/td><\/td>\n<\/tr>\n
703<\/td>ARTEMETHER & LUMEFENTRINE FOR ORAL
\nSUSPENSION <\/td>		EACH 5 ML (AFTER RECONSTITUTION) CONTAINS
\nARTEMETHER IP 40 MG
\nLUMEFANTRINE USP 240 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: TARTRAZINE YELLOW SUPRA
\n<\/td>		<\/td>05.10.2011<\/td><\/td>\n<\/tr>\n
704<\/td>BISOPROLOL FUMARATE TABLETS USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE USP 5 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: FERRIC OXIDE USP NF (RED) & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>27.02.1992<\/td>19.10.2024<\/td>\n<\/tr>\n
705<\/td>BISOPROLOL FUMARATE TABLET USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE IP 2.5 MG
\nEXCIPIENTS Q.S.
\n COLOUR: PONCEAU 4R LAKE & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>19.01.2001<\/td>19.10.2024<\/td>\n<\/tr>\n
706<\/td>BISOPROLOL FUMARATE TABLET USP<\/td>EACH FILM COATED TABLET CONTAINS
\nBISOPROLOL FUMARATE IP 10 MG
\nEXCIPIENTS Q.S.
\n COLOUR: FERRIC OXIDE USP NF (YELLOW), FERRIC OXIDE USP NF (RED) & TITANIUM DIOXIDE IP
\n<\/td>		USP<\/td>27.02.1992<\/td>19.10.2024<\/td>\n<\/tr>\n
707<\/td>SITAGLIPTIN PHOSPHATE AND METFORMIN
\n HYDROCHLORIDE TABLET
\n<\/td>		EACH FILM COATED TABLET CONTAINS
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP 64.25MG
\nEQ. TO SITAGLIPTIN 50 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\n COLOUR: IRON OXIDE RED, IRON OXIDE BLACK & TITANIUM DIOXIDE IP
\n<\/td>		<\/td>28.04.2008<\/td>19.10.2024<\/td>\n<\/tr>\n
708<\/td>SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE TABLET<\/td>EACH FILM COATED TABLET CONTAINS
\nSITAGLIPTIN PHOSPHATE MONOHYDRATE IP 64.25MG
\nEQ. TO SITAGLIPTIN 50 MG
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\nEXCIPIENTS Q.S.
\n COLOUR: IRON OXIDE RED, IRON OXIDE BLACK & TITANIUM DIOXIDE IP
\n<\/td>		<\/td>28.04.2008<\/td>19.10.2024<\/td>\n<\/tr>\n
709<\/td>AMLODIPINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 2.5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>20.05.2009<\/td>19.10.2024<\/td>\n<\/tr>\n
710<\/td>AMLODIPINE & ATENOLOL TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nATENOLOL IP 50 MG
\nEXCIPIENTS Q.S.
\n COLOUR: LAKE OF SUNSET YELLOW FCF
\n<\/td>		IP<\/td>20.05.1996<\/td>19.10.2024<\/td>\n<\/tr>\n
711<\/td>DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUSTAINED-RELEASE)
\n TABLETS<\/td>		EACH UNCOATED BILAYER TABLET CONTAINS
\nDAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE
\nEQ. TO DAPAGLIFLOZIN 10 MG
\nMETFORMIN HYDROCHLORIDE IP 1000 MG
\n(IN SUSTAINED-RELEASE FORM)
\nEXCIPIENTS Q.S.
\nCOLOUR: TITANIUM DIOXIDE IP
\n<\/td>		<\/td><\/td>19.10.2024<\/td>\n<\/tr>\n
712<\/td>GLIMEPIRIDE AND
\nMETFORMIN HYDROCHLORIDE TABLETS
\n<\/td>		EACH UNCOATED TABLET CONTAINS:
\nGLIMEPIRIDE IP 1 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: RED OXIDE OF IRON
\n<\/td>		<\/td><\/td>19.10.2024<\/td>\n<\/tr>\n
713<\/td>GLIMEPIRIDE AND
\nMETFORMIN HYDROCHLORIDE TABLETS
\n<\/td>		EACH UNCOATED TABLET CONTAINS:
\nGLIMEPIRIDE IP 2 MG
\nMETFORMIN HYDROCHLORIDE IP 500 MG
\nEXCIPIENTS Q.S.
\nCOLOUR: QUINOLINE YELLOW
\n<\/td>		<\/td><\/td>19.10.2024<\/td>\n<\/tr>\n
714<\/td>AMLODIPINE TABLETS IP<\/td>EACH UNCOATED TABLET CONTAINS
\nAMLODIPINE BESYLATE IP
\nEQ. TO AMLODIPINE 5 MG
\nEXCIPIENTS Q.S.
\n<\/td>		IP<\/td>20.05.2009<\/td>19.10.2024<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n \n
\n \n
\n\n
\n
\n Rated 4<\/strong> out of 5<\/span>\n <\/div>\n <\/div>\n \n
\n Excellent support and communication on completing the project and shown great degree of flexibility with changing timelines, guidance to team for implementation of solution. <\/div>\n\n \n
\n
\n
\n
\n <\/div>\n <\/div>\n \n
\n Rakesh Malhotra<\/a><\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n \n <\/div>\n \n
\n \n
\n\n
\n
\n Rated 4<\/strong> out of 5<\/span>\n <\/div>\n <\/div>\n \n
\n From my first contact with Xenobiotics I have found them to be a very impressive company. The expert knowledge, exceptional customer service, and attention to detail have been a refreshing change when compared to other companies in the industry. The ability to outsource select products to them has allowed us to meet our operational challenges. In all this Xenobiotics has been very flexible and supportive. <\/div>\n\n \n
\n
\n
\n
\n <\/div>\n <\/div>\n \n
\n Anil Dubay<\/a><\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n \n <\/div>\n \n
\n \n
\n\n
\n
\n Rated 4<\/strong> out of 5<\/span>\n <\/div>\n <\/div>\n \n
\n Lorem ipsum dolor sit amet, quia non consectetur adipiscing elit <\/div>\n\n \n
\n
\n
\n
\n <\/div>\n <\/div>\n \n
\n Rajarshi Sarkar<\/a><\/span>\n August 16, 2020 <\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n \n <\/div>\n <\/div>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

We Are Available. Interested in Collaboration?<\/h2><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n \n \n\t\t\t Get in Touch<\/span>\n\t\t<\/span>\n\n\n <\/a>\n <\/div>\n \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Generic Medicine Drugs Rated 4 out of 5 Excellent support and communication on completing the project and shown great degree of flexibility with changing timelines, guidance to team for implementation of solution. Rakesh Malhotra Rated 4 out of 5 From my first contact with Xenobiotics I have found them to be a very impressive company. … <\/p>\n

<\/i>Read More “Denmark”<\/span><\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-elementor.php","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-9162","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/pages\/9162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/comments?post=9162"}],"version-history":[{"count":13,"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/pages\/9162\/revisions"}],"predecessor-version":[{"id":9231,"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/pages\/9162\/revisions\/9231"}],"wp:attachment":[{"href":"https:\/\/xenobiotics.in\/index.php\/wp-json\/wp\/v2\/media?parent=9162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}